Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Mar. 01, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Dec. 31, 2023 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity File Number | 001-32146 | ||
Entity Registrant Name | DSS, INC. | ||
Entity Central Index Key | 0000771999 | ||
Entity Tax Identification Number | 16-1229730 | ||
Entity Incorporation, State or Country Code | NY | ||
Entity Address, Address Line One | 275 Wiregrass Pkwy | ||
Entity Address, City or Town | Henrietta | ||
Entity Address, State or Province | NY | ||
Entity Address, Postal Zip Code | 14586 | ||
City Area Code | (585) | ||
Local Phone Number | 325-3610 | ||
Title of 12(b) Security | Common Stock, par value $0.02 per share | ||
Trading Symbol | DSS | ||
Security Exchange Name | NYSEAMER | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 20,278,452 | ||
Entity Common Stock, Shares Outstanding | 7,066,772 | ||
Documents Incorporated by Reference [Text Block] | None. | ||
ICFR Auditor Attestation Flag | true | ||
Document Financial Statement Error Correction [Flag] | false | ||
Auditor Firm ID | 606 | ||
Auditor Name | GRASSI & CO., CPAs, P.C. | ||
Auditor Location | Jericho, New York |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 6,615,000 | $ 19,290,000 |
Accounts receivable, net | 3,994,000 | 7,564,000 |
Inventory | 2,819,000 | 7,721,000 |
Current portion of notes receivable | 8,772,000 | 11,719,000 |
Assets held for sale | 51,595,000 | |
Prepaid expenses and other current assets | 839,000 | 1,700,000 |
Total current assets | 74,634,000 | 47,994,000 |
Property, plant and equipment, net | 6,417,000 | 13,391,000 |
Investment in real estate, net | 6,279,000 | 55,029,000 |
Other investments | 1,282,000 | 1,534,000 |
Investment, equity method | 128,000 | 162,000 |
Marketable securities | 9,979,000 | 27,307,000 |
Notes receivable | 111,000 | 922,000 |
Other assets | 97,000 | 2,699,000 |
Right-of-use assets | 7,210,000 | 8,219,000 |
Goodwill | 26,862,000 | 60,919,000 |
Other intangible assets, net | 20,193,000 | 30,740,000 |
Total assets | 153,192,000 | 248,916,000 |
Current liabilities: | ||
Accounts payable | 3,654,000 | 5,914,000 |
Accrued expenses and deferred revenue | 2,512,000 | 19,341,000 |
Other current liabilities | 983,000 | 447,000 |
Current portion of lease liability | 686,000 | 796,000 |
Current portion of long-term debt, net | 47,776,000 | 47,161,000 |
Total current liabilities | 55,611,000 | 73,689,000 |
Long-term debt, net | 7,451,000 | 10,181,000 |
Long-term lease liability | 6,917,000 | 7,820,000 |
Other long-term liabilities | 507,000 | |
Deferred tax liability, net | 38,000 | |
Commitments and contingencies (Note 17) | ||
Stockholders’ equity | ||
Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2022); Liquidation value $1,000 per share, zero aggregate. zero on December 31, 2022) | ||
Common stock, $.02 par value; 200,000,000 shares authorized, 7,066,772 shares issued and outstanding (6,950,858 on December 31, 2022) | 140,000 | 139,000 |
Additional paid-in capital | 319,963,000 | 319,766,000 |
Accumulated deficit | (256,176,000) | (194,343,000) |
Total DSS stockholders’ equity | 63,927,000 | 125,562,000 |
Non-controlling interest in subsidiary | 19,286,000 | 31,119,000 |
Total stockholders’ equity | 83,213,000 | 156,681,000 |
Total liabilities and stockholders’ equity | $ 153,192,000 | $ 248,916,000 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.02 | $ 0.02 |
Preferred stock, shares authorized | 47,000 | 47,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Preferred stock, liquidation preference per share | $ 1,000 | $ 1,000 |
Preferred stock, liquidation preference | $ 0 | $ 0 |
Common stock, par value | $ 0.02 | $ 0.02 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 7,066,772 | 6,950,858 |
Common stock, shares outstanding | 7,066,772 | 6,950,858 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue: | ||
Total revenue | $ 30,258,000 | $ 47,307,000 |
Costs and expenses: | ||
Cost of revenue | 26,647,000 | 40,247,000 |
Selling, general and administrative (including stock-based compensation) | 25,072,000 | 53,531,000 |
Total costs and expenses | 51,719,000 | 93,778,000 |
Operating loss | (21,461,000) | (46,471,000) |
Other income (expense): | ||
Interest income | 1,289,000 | 629,000 |
Dividend income | 16,000 | 159,000 |
Other income | 532,000 | 3,602,000 |
Interest expense | (553,000) | (126,000) |
Litigation loss | (8,750,000) | |
Gain on extinguishment of debt | 110,000 | |
Loss on equity method investment | (34,000) | 129,000 |
Loss on investments | (32,986,000) | (10,697,000) |
Impairment of investment | (5,637,000) | |
Impairment of fixed assets | (2,843,000) | |
Impairment of intangible assets | (7,418,000) | |
Impairment of investment in real estate | (812,000) | |
Impairment of goodwill | (30,978,000) | |
Provision for loan losses | (3,794,000) | |
Loss on sale of assets | (1,300,000) | 405,000 |
Loss before income taxes | (97,499,000) | (69,490,000) |
Income tax loss | (4,000) | (172,000) |
Net loss | (97,503,000) | (69,662,000) |
Net loss attributed to noncontrolling interest | 16,897,000 | 9,822,000 |
Net loss attributable to common stockholders | $ (80,606,000) | $ (59,840,000) |
Loss per common share: | ||
Basic | $ (11.52) | $ (10.72) |
Diluted | $ (11.52) | $ (10.72) |
Shares used in computing loss (earnings) per common share: | ||
Basic | 6,996,322 | 5,581,106 |
Diluted | 6,996,322 | 5,581,106 |
Printed Products [Member] | ||
Revenue: | ||
Total revenue | $ 18,497,000 | $ 17,973,000 |
Rental Revenue Income [Member] | ||
Revenue: | ||
Total revenue | 3,647,000 | 6,287,000 |
Management Revenue Fee Income [Member] | ||
Revenue: | ||
Total revenue | 134,000 | |
Net Investment Revenue Income [Member] | ||
Revenue: | ||
Total revenue | 385,000 | 630,000 |
Direct Marketing [Member] | ||
Revenue: | ||
Total revenue | 6,088,000 | 21,989,000 |
Commission Revenue [Member] | ||
Revenue: | ||
Total revenue | $ 1,641,000 | $ 294,000 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Cash flows from operating activities: | ||
Net loss from operations | $ (97,503,000) | $ (69,662,000) |
Adjustments to reconcile net loss from operations to net cash used by operating activities: | ||
Depreciation and amortization | 5,206,000 | 12,925,000 |
Stock based compensation | 4,000 | |
Gain/(loss) on equity method investment | 34,000 | (129,000) |
Loss on investments | 33,506,000 | 13,386,000 |
Change in ROU assets | 1,009,000 | (7,721,000) |
Gain on extinguishment of debt | (110,000) | |
Deferred tax loss | 38,000 | |
Loss on sales of assets | 1,300,000 | |
Impairment of fixed assets | 2,843,000 | |
Impairment of intangible assets | 7,418,000 | |
Impairment of real estate | 812,000 | |
Impairment of Goodwill | 30,978,000 | |
Impairment of accounts receivable | 3,023,000 | |
Impairment of notes receivable | 3,794,000 | 1,525,000 |
Impairment of other investments | 5,637,000 | |
Decrease (increase) in assets: | ||
Accounts receivable | 1,316,000 | (1,891,000) |
Inventory | 5,483,000 | 540,000 |
Prepaid expenses and other current assets | 996,000 | 1,766,000 |
Other assets | 2,392,000 | (2,210,000) |
Increase (decrease) in liabilities: | ||
Accounts payable | (2,260,000) | 3,994,000 |
Accrued expenses | (15,646,000) | 4,307,000 |
Change in ROU liabilities | (1,013,000) | |
Other liabilities | (39,000) | (298,000) |
Net cash used by operating activities | (19,194,000) | (26,953,000) |
Cash flows from investing activities: | ||
Purchase of property, plant and equipment | (818,000) | (2,294,000) |
Purchase of real estate | (732,000) | |
Purchase of investment | (195,000) | |
Purchase of marketable securities | (14,884,000) | |
Disposal of property, plant & equipment | 248,000 | 2,152,000 |
Asset acquired with APB acquisition | (1,879,000) | |
Asset acquired with Sentinel acquisition | 40,000 | |
Conversion of SHRG to consolidation | 3,038,000 | |
Change in Equity investment | (113,000) | |
Issuance of new notes receivable, net origination fees | (1,046,000) | (3,621,000) |
Payment received on notes receivable | 1,010,000 | 1,067,000 |
Sale of marketable securities | 9,502,000 | |
Purchase of intangible assets | (508,000) | |
Net cash provided (used) by investing activities | 8,936,000 | (17,969,000) |
Cash flows from financing activities: | ||
Payments of long-term debt | (4,246,000) | (3,504,000) |
Borrowings of long-term debt | 1,829,000 | 9,602,000 |
Issuances of common stock, net of issuance costs | 1,519,000 | |
Net cash (used) provided by financing activities | (2,417,000) | 7,617,000 |
Net decrease in cash | (12,675,000) | (37,305,000) |
Cash and cash equivalents at beginning of year | 19,290,000 | 56,595,000 |
Cash and cash equivalents at end of year | $ 6,615,000 | $ 19,290,000 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Equity - USD ($) | Common Stock [Member] | Preferred Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Parent [Member] | Noncontrolling Interest [Member] | Total |
Balance at Dec. 31, 2021 | $ 80,000 | $ 296,199,000 | $ (134,503,000) | $ 161,776,000 | $ 36,409,000 | $ 198,185,000 | |
Balance, shares at Dec. 31, 2021 | 3,987,308 | ||||||
Issuance of common stock, net of expenses | $ 43,000 | 17,362,000 | 17,405,000 | 17,405,000 | |||
Issuance of common stock, net of expenses, shares | 2,146,200 | ||||||
Acquisition of Sentinel Brokers Company, Inc. | 1,274,000 | 1,274,000 | |||||
Acquisition of Sharing Services Global Corporation | 3,257,000 | 3,257,000 | |||||
Stock based payments | $ 16,000 | 6,205,000 | 6,221,000 | 6,221,000 | |||
Stock based payments, shares | 817,350 | ||||||
Net loss | (59,840,000) | (59,840,000) | (9,821,000) | (69,661,000) | |||
Acquisition of Sentinel Brokers Company, Inc. shares | (1,274,000) | (1,274,000) | |||||
Balance at Dec. 31, 2022 | $ 139,000 | 319,766,000 | (194,343,000) | 125,562,000 | 31,119,000 | 156,681,000 | |
Balance, shares at Dec. 31, 2022 | 6,950,858 | ||||||
Issuance of common stock, net of expenses | $ 1 | 267,000 | 268,000 | 268,000 | |||
Issuance of common stock, net of expenses, shares | 62,354 | ||||||
Acquisition of Sentinel Brokers Company, Inc. | 70,000 | 70,000 | 70,000 | ||||
Net loss | (80,606,000) | (80,606,000) | (16,897,000) | (97,503,000) | |||
Acquisition of Sentinel Brokers Company, Inc. shares | (70,000) | (70,000) | (70,000) | ||||
Fractional shares as a result of reverse stock split | |||||||
Fractional shares as a result of reverse stock split, shares | 53,560 | ||||||
Deconsolidation of Sharing Services Global Corporation | 18,773,000 | 18,773,000 | 5,064,000 | 23,837,000 | |||
Balance at Dec. 31, 2023 | $ 140,000 | $ 319,963,000 | $ (256,176,000) | $ 63,927,000 | $ 19,286,000 | $ 83,213,000 | |
Balance, shares at Dec. 31, 2023 | 7,067,772 |
Description of Business
Description of Business | 12 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Description of Business | 1. DESCRIPTION OF BUSINESS Description of Business The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS”. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation (discontinued in 2023), (8) Secure Living (discontinued in 2023), and (9) Alternative Energy (discontinued in 2023). Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation (discontinued in 2023). (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing (discontinued in 2023). (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy (discontinued in 2023). On May 13, 2021, Sentinel Brokers, LLC. (“Sentinel LLC”), subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9% 75% 5% 80.1% On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.34 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Summary of Significant Accounting Policies Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 280 7% 81% s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). Subsequent to April 30, 2023, the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 74,000 Use of Estimates Reclassifications Cash Equivalents Accounts Receivable At December 31, 2023, and December 31, 2022, the Company established a reserve for credit losses of approximately $ 2,494,000 29,000 5,673,000 7,564,000 3,994,000 Concentration of Credit Risk 14% 6% 36% 17% 20% 11% 39% 30% Notes receivable, unearned interest, and related recognition Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” Investments Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory adjust the inventory balance for obsolete and slow-moving items. An allowance for obsolescence of approximately $ 18,000 and $ 57,000 associated with the inventory at our Premier subsidiary for December 31, 2023 and 2022, respectively. Also, SHRG had an allowance for obsolescence of approximately $ 685,000 Property, Plant and Equipment Investments in real estate, net Leases The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period incurred. The Company has elected to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities. Impairment of Long-Lived Assets and Goodwill Assets held for sale – The Company has several buildings and the associated land they occupy for sale as of December 31, 2023. These consist of primarily of retail space in Lindon, Utah approximating $ 5,593,000 41,541,000 4,396,000 65,000 Goodwill 1,769,000 25,093,000 APB, and Sentinel Co. of approximately $ 29,744,000 , and $ 1,234,000 respectively, were deemed impaired and written off at December 31, 2023. Intangible Assets 7,418,000 Revenue As of December 31, 2023, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Costs of revenue - Shipping and Handling Costs Share-Based Payments Sales Commissions no Contingent Legal Expenses - Research and Development 1,147,000 1,256,000 Income Taxes Loss Per Common Share 5,000 For the year-ended December 31, 2023, potential dilutive instruments 0 Acquisitions Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are expensed as incurred. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. Business Combinations Continuing Operations and Going Concern - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. While the Company has approximately $ 6.6 Aside from its $ 6.6 million in cash as of December 31, 2023, the Company believes it can continue as a going concern, due to its ability to generate operating cash through the sale of its $ 10.0 million of Marketable Securities, and the anticipated receipts of principal and interest on its Notes receivable of approximately $ 8.8 million through December 31, 2024. The Company has also taken steps to sell its real estate holdings in Utah, Texas, Pennsylvania, and Florida. These properties approximate $ 51.6 |
Inventory
Inventory | 12 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory | 3. Inventory Inventory consisted of the following as of December 31: Schedule of Inventory 2023 2022 Finished Goods $ 2,218,000 $ 6,779,000 Work in Process 180,000 403,000 Raw Materials 439,000 1,281,000 Inventory Gross $ 2,837,000 $ 8,463,000 Less allowance for obsolescence (18,000 ) (742,000 ) Inventory Net $ 2,819,000 $ 7,721,000 |
Notes Receivable
Notes Receivable | 12 Months Ended |
Dec. 31, 2023 | |
Receivables [Abstract] | |
Notes Receivable | 4. Notes Receivable Note 1 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered a convertible promissory note (“Note 1”) with Borrower 1, a company registered in the state of Texas. Note 1 has an aggregate principal balance up to $ 5,000,000 6.65 May 1, 2023 Note 1 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 1 with the maximum principal amount equal to 18% of the total equity position of Borrower 1 at conversion 5,544,000 5,420,000 2,772,000 Note 2 On September 23, 2021, APB entered into refunding bond anticipatory note (“Note 2”) with Borrower 2, which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code ; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 5.59 September 22, 2022 September 19, 2024 3,910,000 3,701,000 Note 3 On October 25, 2021, APB entered into a loan agreement (“Note 3”) with Borrower 3, a company registered in the state of Utah. Note 3 has an initial aggregate principal balance up to $ 1,000,000 3,000,000 8.0 October 25, 2022 This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. 884,000 Note 4 On May 14, 2021, APB extended the credit (“Note 4”) to an individual (“Borrower 4”) in the form of two promissory notes for $ 250,000 10,000 12.5 May 15, 2023 252,000 9,000 Note 5 On October 27, 2021, HWH World, Inc., a subsidiary of the Company entered a revolving loan commitment (“Note 5”) with Borrower 5, a company registered in Taiwan. The outstanding principal and interest at December 31, 2023 and December 31, 2022 is $ 0 63,000 Note 6 On December 28, 2021, APB entered into a promissory note (“Note 6”) with Borrower 6, a company registered in the state of California. Note 6 has a principal balance of $ 700,000 12.0 December 28, 2022 May 31, 2023 50,000 253,000 701,000 Note 7 On January 24, 2022, APB and Borrower 7 entered into a promissory note (“Note 7”) in the principal sum of $ 100,000 6 January 2024 103,000 106,000 Note 8 On March 2, 2022, APB and Borrower 8, a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 8”). Under the terms of Note 8, APB at its discretion, may lend up to the principal sum of $ 893,000 8 March 2024 446,000 3,500 874,000 25,000 Note 9 On May 9, 2022, DSS PureAir and Borrower 9 entered into a promissory note (“Note 9”) in the principal sum of $ 210,000 10 February 9, 2023 224,000 112,000 213,000 Note 10, related party On August 29, 2022, DSS Financial Management Inc and Borrower 10, a related party, entered into a promissory note (“Note 10”) in the principal sum of $ 100,000 8 August 29, 2025 100,000 100,000 76,000 24,000 24.9 Note 11, related party On July 26, 2022, APB and Borrower 11 entered into a promissory note (“Note 11”) in the principal sum of $ 1,000,000 8 July 26, 2024 939,000 20,000 924,000 66,000 Note 12, related party On June 15, 2022, DSS and Borrower 12, entered into a convertible promissory note (“Note 12”) in the principal sum of $ 27,000,000 8 0.03 June 14, 2024 26,000 0.0001 1,000 Note 13 On February 19, 2021, Impact BioMedical, Inc, entered into a promissory note with an individual. The Company loaned the principal sum of $ 206,000 6.5 August 19, 2022 203,000 206,000 16,000 190,000 Note 14 On May 8, 2023, DSS Financial Management Inc and Borrower 14 entered into a promissory note (“Note 14”) in the principal sum of $ 102,000 2 10.5 May 7, 2026 107,000 53,000 54,000 Note 15 On June 27, 2023, DSS and Borrower 15 entered into a convertible promissory note (“Note 15”) in the principal sum of $ 1,400,000 300,000 10 September 1, 2024 Note 16 On March 31,2023, DSS Biohealth Security, Inc and Borrower 16 entered into a promissory note (“Note 16”) in the principal sum of $ 140,000 8.5 March 31, 2025 133,000 99,000 34,000 Note 17 On September 28, 2023, APB and Borrower 17 entered into a promissory note (“Note 17”) in the principal sum of $ 400,000 5 November 12, 2023 Note 18 On August 11, 2022, APB and Borrower 18 entered into a promissory note (“Note 18”) in the principal sum of $ 1,430,000 8 August 12, 2024 1,102,000 375,000 |
Provision for Credit Losses
Provision for Credit Losses | 12 Months Ended |
Dec. 31, 2023 | |
Provision For Credit Losses | |
Provision for Credit Losses | 5. Provision for Credit Losses Effective January 1, 2022, the Company adopted amended accounting guidance “ ASU No.2016-13 – Credit Losses” Accounts receivable are stated at the amount owed by the customer. The Company maintains an allowance for credit losses for accounts receivable and unbilled receivables, based on expected credit losses resulting from the inability of our customers to make required payments. The allowance for credit losses is estimated based on historical experience, current economic conditions and the creditworthiness of customers. Receivables are charged to the allowance when determined to be no longer collectible. The Company regularly monitors and assesses its risk of not collecting amounts owed by customers and records its allowance for credit losses based on the results of this analysis. As of December 31, 2023, we have reviewed the entire loan portfolio as well as all financial assets of the Company for the purpose of evaluating the loan portfolio and the loan balances, including a review of individual and collective portfolio loan quality, loan(s) performance, including past due status and covenant defaults, assessment of the ability of the borrower to repay the loan on the loan terms, whether any loans should be placed on nonaccrual or returned to accrual, any concentrations in any single borrower and/or industry that we might need to further manage, and if any specific or general loan loss reserve should be established for the entire loan portfolio or for any specific loan. We analyzed the loan loss reserve from three basis: general loan portfolio reserves; industry portfolio reserves, and specific loan loss reserves. As of year-ended December 31, 2023 and December 2022, the Company recorded a Loan loss reserve of approximately $ 4,933,000 1,041,000 General Loan Portfolio Reserve - 194,000 145,000 Industry Portfolio Reserves – Specific Loan Reserves - 884,000 2,884,000 1,046,000 1,102,000 The following table identifies the loan loss reserve for the period ending December 31, : Schedule of Loan Loss Reserve 2023 2022 General Loan Portfolio Reserve $ 194,000 $ 145,000 Specific Loan Reserves $ 5,916,000 $ 896,000 Total $ 6,110,000 $ 1,041,000 Changes in the allowance for doubtful accounts and loan loss reserve were as follows: Schedule of Allowance for Doubtful Accounts and Loan Loss Reserve Allowance for credit losses Loan loss reserve Total Balance at January 1, 2022 $ 20,000 $ - $ 20,000 Adoption of CECL - 1,041,000 1,041,000 Bad debt expense 9,000 - 9,000 Write-offs - - - Recoveries - - - Balance at December 31, 2022 29,000 1,041,000 1,070,000 Bad debt expense 2,000 5,069,000 5,071,000 Write-offs 3,500,000 - 3,500,000 Recoveries (1,037,000 ) - (1,037,000 ) Balance at December 31, 2023 $ 2,494,000 $ 6,110,000 $ 8,604,000 |
Financial Instruments
Financial Instruments | 12 Months Ended |
Dec. 31, 2023 | |
Investments, All Other Investments [Abstract] | |
Financial Instruments | 6. FINANCIAL INSTRUMENTS Financial Instruments Cash, Cash Equivalents and Marketable Securities The following tables show the Company’s cash and marketable securities by significant investment category as of December 31: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Cost Unrealized Gain/Loss Fair Value Cash And Cash Equivalents Marketable Securities Cash $ 6,545,000 $ - $ 6,545,000 $ 6,545,000 $ - Level 1 Money Market Funds 70,000 - 70,000 70,000 - Marketable Securities 27,304,000 (17,325,000 ) 9,979,000 - 9,979,000 Total $ 33,919,000 $ (17,325,000 ) $ 16,594,000 $ 6,615,000 $ 9,979,000 2022 Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investment Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 45,283,000 (17,976,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities 1,023,000 - 1,023,000 - - 1,023,000 Total $ 68,914,000 $ (17,976,000 ) $ 50,938,000 $ 19,290,000 $ 27,307,000 $ 4,341,000 The following tables shows the Company’s net unrealized (loss) gain recognized during the year on marketable securities still held as of December 31: Schedule of Net Unrealized (Loss) Gain Recognized on marketable Securities 2023 2022 Net gains (losses) recognized during the year on marketable securities $ (5,521,000 ) $ (2,757,000 ) Less: Net gains (losses) realized during the year on marketable securities sold during the period (1,973,000 ) 1,077,000 Net unrealized gain (loss) recognized during the reporting year on marketable securities still held at the reporting date $ (3,548,000 ) $ (3,834,000 ) The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio. |
Disposal of Assets
Disposal of Assets | 12 Months Ended |
Dec. 31, 2023 | |
Disposal Of Assets | |
Disposal of Assets | 7. Disposal of assets Disposal of Assets On July 1 st 1,000 706,000 758,000 698,000 59,000 the agreement includes payment of 1% royalty, starting November 1, 2023, being defined as 1% of the gross sale price of all Seller’s new products made and sold outside of existing inventory on the schedule, for a period ending October 31, 2033. 639,000 On July 1 st 100 259,000 617,000 |
Investments
Investments | 12 Months Ended |
Dec. 31, 2023 | |
Investments, All Other Investments [Abstract] | |
Investments | 8. Investments Alset International Limited related party The Company owns 127,179,291 4 3,269,000 3,319,000 50,000 1,590,000 West Park Capital, Inc. On December 30, 2020, the Company signed a binding letter of intent with West Park Capital, Inc (“West Park”) and Century TBD Holdings, LLC (“TBD”) where the parties agreed to prepare a note and stock exchange agreement whereby DSS will assign the TBD Note to West Park and West Park shall issue to DSS a stock certificate reflecting 7.5 500,000 BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9 100,000 10 100,000 24.9 20 34,000 20,000 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99 632,000 Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 1.00 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $ 1.00 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 16 4,035,000 100 4,100,000 Stemtech Corporation In September 2021, the Company’s former subsidiary SHRG, Stemtech Corporation (“Stemtech”) and Globe Net Wireless Corp. (“GNTW”) entered into a Securities Purchase Agreement (the “SPA”) pursuant to which SHRG invested $ 1.4 1.4 500,000 September 9, 2024 10 1.4 154,173 0 44,000 0 39,000 In September 2021, SHRG entered into a Membership Unit Purchase Agreement pursuant to which the SHRG acquired a 30.75 1,537,000 100 |
Property Plant and Equipment an
Property Plant and Equipment and Investment in Real Estate, Net | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Property Plant and Equipment and Investment in Real Estate, Net | 9. PROPERTY PLANT AND EQUIPMENT AND INVESTMENT IN REAL ESTATE, NET Property Plant and Equipment and Investment in Real Estate, Net Property, plant and equipment consisted of the following as of December 31, 2023: Schedule of Property, Plant and Equipment Estimated Useful Life 2023 2022 Machinery and equipment 5 10 $ 9,974,000 $ 9,170,000 Building and improvements 39 294,000 5,103,000 Land - 1,817,000 Furniture and fixtures 7 432,000 501,000 Software and websites 3 273,000 320,000 Construction in progress 365,000 667,000 Total Cost 11,338,000 17,578,000 Less accumulated depreciation 4,921,000 4,187,000 Property, plant and equipment, net $ 6,417,000 $ 13,391,000 Depreciation expense for the years ended December 31, 2023 and 2022 was $ 802,000 1,569,000 Real Estate consisted of the following at December 31: Schedule of Investment in Real Estate Estimated Useful Life 2023 2022 Building and improvements 1 30 $ 5,273,000 $ 42,665,000 Land 1,600,000 14,861,000 Total Cost 6,873,000 57,526,000 Less: accumulated depreciation 594,000 2,497,000 Investment in real estate $ 6,279,000 $ 55,029,000 Depreciation expense for the years ended December 31, 2023 and 2022 was $ 2,085,000 2,077,000 |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | 10. INTANGIBLE ASSETS Intangible Assets On August 25, 2022, DSS PureAir, a subsidiary of the Company finalized an asset purchase agreement with Celios Corporation (“Celios”) to acquire inventory, patents, and other intangible assets associated with that inventory, and other intangible assets from Celios for $ 900,000 409,000 3 20 Intangible assets are comprised of the following as of December 31: Schedule of Intangible Assets 2023 2022 Useful Life Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology assets 20 $ 22,260,000 $ 3,340,000 - 18,920,000 $ 22,260,000 $ 2,226,000 $ 20,034,000 Acquired intangibles customer lists, licenses, non-compete agreements, branding, product formulas, tenant improvements, in-place, favorable and unfavorable leases 1 11 19,245,000 10,613,000 7,418,000 1,214,000 20,023,000 9,397,000 10,626,000 Acquired intangibles patents and patent rights 500,000 500,000 - - 500,000 500,000 - Patent application costs Varied 1,052,000 993,000 - 59,000 1,052,000 972,000 80,000 $ 43,057,000 $ 15,446,000 $ 7,418,000 $ 20,193,000 $ 43,835,000 $ 13,095,000 $ 30,740,000 (1) Patent application costs are amortized over their expected useful life which is generally the remaining legal life of the patent. As of December 31, 2023, the weighted average remaining useful life of these assets in service was approximately 1.7 Amounts amortized for the year ended December 31, 2023 and 2022 was approximately $ 2,319,000 $ 9,279,000 Expected amortization for each of the five succeeding fiscal years is as follows: Schedule of Estimated Future Amortization of Intangible Assets Year Amount 2024 3,012,000 2025 3,009,000 2026 2,869,000 2027 2,869,000 2028 2,860,000 Thereafter 5,574,000 |
Accrued Expenses and Deferred R
Accrued Expenses and Deferred Revenue | 12 Months Ended |
Dec. 31, 2023 | |
Accrued Expenses And Deferred Revenue | |
Accrued Expenses and Deferred Revenue | 11. ACCRUED EXPENSES AND DEFERRED REVENUE Accrued Expenses and Deferred Revenue Accrued expenses and deferred revenue consist of the following for the year ended December 31: Summary of Accrued Expenses and Deferred Revenue 2023 2022 Customer deposits $ 222,000 $ 188,000 Deferred revenue - 519,000 Accrued wages 812,000 4,014,000 Settlement liability - 8,974,000 Uncertain tax positions - 926,000 Accrued expenses 1,468,000 4,536,000 Income tax payable - 172,000 Sales tax payable 10,000 12,000 Accrued expenses and deferred revenue $ 2,512,000 $ 19,341,000 |
Short Term and Long-Term Debt
Short Term and Long-Term Debt | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Short Term and Long-Term Debt | 12. SHORT TERM AND LONG-TERM DEBT Short Term and Long-Term Debt Promissory Notes - 200,000 8.0 5.00 200,000 On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,710,000 2,932,000 3,406,000 4.63 491,000 2,442,000 On August 1, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 5,105,000 4.25 The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months 2,829,000 4.25 40,000 4,640,000 1,600,000 325,000 585,000 3 6,729,000 206,000 4,402,000 50,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 547,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 2,131,000 3,008,000 On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 62,000,000 32,100,000 12,100,000 1,500,000 15,901,000 1 11 52,407,000 The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28 8.46 November 2, 2023 November 2, 2024 40,193,000 270,000 41,331,000 3,773,000 2,418,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 677,000 346,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4,500,000 3,200,000 1,000,000 222,000 29,000 5 4,450,000 25 4.28 17,000 2,977,000 60,000 2,952,000 25,000 153,000 On March 30, 2023, Premier Packaging, a subsidiary of the Company entered into a loan and security agreement with Union Bank & Trust Company for the principal amount of $ 790,000 7.44 14,000 719,000 112,000 607,000 A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to December 31, 2023 are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2024 $ 47,776,000 2025 859,000 2026 901,000 2027 947,000 2028 1,200,000 Thereafter 3,544,000 Total 55,227,000 |
Lease Liability
Lease Liability | 12 Months Ended |
Dec. 31, 2023 | |
Lease Liability | |
Lease Liability | 13. Lease Liability The Company has operating leases predominantly for operating facilities. As of December 31, 2023, the remaining lease terms on our operating leases range from less than one twelve years Future minimum lease payments as of December 31, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2024 956,000 2025 861,000 2026 839,000 2027 808,000 2028 824,000 After 4,913,000 Total lease payments 9,201,000 Less: Imputed Interest (1,598,000 ) Present value of remaining lease payments $ 7,603,000 Current $ 686,000 Noncurrent $ 6,917,000 Weighted-average remaining lease term (years) 14.3 Weighted-average discount rate 4.1 % In March of 2022, Premier Packaging began leasing its relocated manufacturing facilities to West Henrietta, New York. This lease contains an escalating payment clause, ranging from $ 61,000 78,000 790,000 975,000 |
Stockholders_ Equity
Stockholders’ Equity | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Stockholders’ Equity | 14. STOCKHOLDERS’ EQUITY Stockholders’ Equity Equity transactions On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On March 10, 2022, the Company issued 894,084 340,000 On May 5, 2022, the Company issued 63,205 29,000 On May 25, 2022, the Company issued 15,389,995 5,848,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.41 On April 10, 2023, the Company issued 62,354 268,000 On January 4, 2024 the Company effected a reverse stock split of 1 for 20 140,264,240 139,017,000 7,066,772 6,950,858 Stock-Based Compensation – 4,000 none Stock Warrants Equity Incentive Plan 241,204 In addition, on the first day of each calendar year, for a period of not more than ten (10) years, commencing January 1, 2021, or the first business day of the calendar year if the first day of the calendar year falls on a Saturday or Sunday, the shares available under this plan will automatically increase in an amount equal to the lesser of (i) five percent (5%) of the total number of shares of Common Stock outstanding as of December 31 of the preceding fiscal year or (ii) such number of shares of Common Stock as determined by the Board of Directors. 460,846 Stock Options 50,000 5,333 no Impact BioMedical, Inc. Equity Transactions – On August 8, 2023 DSS BioHealth Securities, Inc. (“DSS BioHealth”), a wholly-owned subsidiary of the Company, and the sole shareholder of Impact BioMedical Inc., distributed to the shareholders of DSS on record as of July 10, 2023 4 shares of Impact Bio’s stock for 1 share they owned of DSS stock. Each share of Impact BioMedical distributed as part of the distribution will not be eligible for resale until 180 days from the date Impact BioMedical’s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company to lift the restriction sooner. On October 31, 2023, Impact BioMedical effected a reverse stock split of 1 for 55 3,877,282,251 70,496,041 60,496,041 60,496,041 88 12 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 15. INCOME TAXES Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance for the amount of tax benefits which are not expected to be realized. The following is a summary of the components giving rise to the income tax provision (benefit) for the years ended December 31: The provision (benefit) for income taxes consists of the following: Schedule of Income Tax Provision 2023 2022 Currently payable: Federal $ - $ 15,000 State 4,000 - Foreign - 119,000 Total currently payable 4,000 134,000 Deferred: Federal (5,392,000 ) (14,839,000 ) State (79,000 ) (492,000 ) Foreign (48,000 ) (58,000 ) Total deferred (5,519,000 ) (15,390,000 ) Less: increase in allowance 5,519,000 15,427,000 Net deferred - 38,000 Total income tax loss (benefit) $ 4,000 $ 172,000 Individual components of deferred tax assets and liabilities are as follows: Schedule of Deferred Tax Assets and Liabilities 2023 2022 Deferred tax assets: Net operating loss carry forwards $ 21,496,000 $ 24,975,000 Net operating loss IRC 382 limited 9,634,000 9,634,000 Unrealized loss on securities 4,655,000 5,753,000 Equity issued for services 190,000 190,000 Goodwill and other intangibles 63,000 34,000 Investment in pass-through entity 11,000 11,000 Deferred revenue 176,000 176,000 Operating Lease Liability 1,713,000 1,935,000 Depreciation and amortization 1,000 24,000 Other 2,507,000 696,000 Gross deferred tax assets 40,446,000 33,794,000 Deferred tax liabilities: Goodwill and other intangibles 3,369,000 2,822,000 Depreciation and amortization 614,000 (194,000 ) Right -of-use asset 1,625,000 1,846,000 Gross deferred tax liabilities 5,608,000 4,474,000 Less: valuation allowance (34,838,000 ) (29,357,000 ) Net deferred tax liabilities $ - $ (38,000 ) At December 31, 2023 and 2022, the Company has approximately $ 138.9 108.4 43.8 2.9 20.7 43.6 expire through 2043 The valuation allowance for deferred tax assets increased approximately $ 5.5 15.4 1.1 9.9 The differences between the United States statutory federal income tax rate and the effective income tax rate in the accompanying consolidated statements of operations are as follows: Schedule of Effective Income Tax Rate Reconciliation 2023 2022 Statutory United States federal rate 21.0 % 21.0 % State income taxes net of federal benefit 0.38 % 0.51 % Permanent differences (6.68 )% 0.03 % Other (9.04 )% 0.93 % Foreign taxes - % (0.07 )% Change in valuation allowance (5.66 )% (22.66 )% Effective rate - % (0.25 )% The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2023 and 2022 the Company recognized no The Company files income tax returns in the U.S. federal jurisdiction and various states. The tax years 2020-2023 generally remain open to examination by major taxing jurisdictions to which the Company is subject. |
Defined Contribution Pension Pl
Defined Contribution Pension Plan | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
Defined Contribution Pension Plan | 16. DEFINED CONTRIBUTION PENSION PLAN Defined Contribution Pension Plan The Company maintains a qualified employee savings plans (the “401(k) Plan”) that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code and which covers all eligible employees. Employees generally become eligible to participate in the 401(k) Plan two months following the employee’s hire date. Employees may contribute a percentage of their earnings, subject to the limitations of the Internal Revenue Code. Commencing on January 1, 2018, the Company matched 100 50 3.5 124,000 124,000 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 17. COMMITMENTS AND CONTINGENCIES Commitments and Contingencies License Agreement In exchange, the Licensee shall pay the Company a royalty of 5.5% 50% 1,250,000 Employment Agreements Legal Proceedings Maiden Biosciences Litigation On February 15, 2021, Maiden Biosciences, Inc. (“Maiden”) commenced an action against DSS, Inc. (“DSS”), Decentralized Sharing Systems, Inc. (“Decentralized”), HWH World, Inc. (“HWH”), RBC Life International, Inc. (RBC International) (together, the “DSS Defendants”), Frank D. Heuszel (“Heuszel”), RBC Life Sciences, Inc (“RBC”), Steven E. Brown, Clinton Howard, and Andrew Howard (collectively, “Defendants”). The lawsuit is currently pending in the United States District Court Northern District of Texas, Dallas Division, and is styled and numbered Maiden Biosciences, Inc. v. Document Security Stems, Inc., et al., Case No. 3:21-cv-00327. This lawsuit relates to two promissory notes executed by RBC in the 4 th . On March 30, 2021, Defendants DSS, Decentralized, HWH, RBC International, and Heuszel filed a motion to dismiss seeking to dismiss Maiden’s unjust enrichment, exemplary damages, and RICO claims against DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel, as well as Maiden’s fraudulent transfer claims against DSS and RBC International. On August 9, 2021, the Court then entered an order granting in part the motion to dismiss filed on behalf of DSS, Decentralized, HWH, RBC International, and Heuszel. Among other things, the Court held that Maiden failed to plausibly plead certain causes of action, including (1) the civil RICO claim against DSS, Decentralized, HWH, RBC International, and Heuszel, (2) the TUFTA claim against DSS, and (3) the unjust enrichment claim against DSS and RBC International. Notably, the Court declined the request to dismiss the TUFTA claim against RBC International. On September 3, 2021, Maiden filed its first amended complaint, asserting a single cause of action against the DSS Defendants, Heuszel, and RBC for an alleged TUFTA violation. Generally, Maiden sought the same relief requested in its original complaint. Maiden, however, abandoned its request for treble damages. On September 17, 2021, the DSS Defendants filed a motion to dismiss the amended complaint seeking to dismiss Maiden’s TUFTA claim to the extent it seeks to avoid a transfer of assets owned by any of RBC’s subsidiaries, including but not limited to RBC Life Sciences USA, Inc. (“RBC USA”). Further, the motion to dismiss sought the dismissal of Maiden’s TUFTA claim against Heuszel. On November 19, 2021, the Court granted the motion to dismiss in part, dismissing Maiden’s claim against Heuszel and determined Maiden failed to plead that it was a creditor of RBC USA or RBC’s other subsidiaries. However, the Court permitted Maiden to replead once again. On December 17, 2021, Maiden filed its second amended complaint which asserted a single TUFTA claim against only the DSS Defendants, RBC, and RBC USA. During the discovery period, the Parties conducted written discovery, production of documents, and depositions of fact witnesses and expert witnesses. The discovery period closed on August 9, 2022. The DSS Defendants have engaged Stout Risius Ross, LLC (“Stout”) to provide expert opinions regarding the value of the assets at issue. The trial in this matter began on December 12, 2022. The Company vigorously defended its position that Maiden should recover nothing on its TUFTA claim. The DSS Defendants’ experts at Stout provided expert opinions regarding the value of the assets at issue and the deficiencies with Maiden’s designated expert’s opinions. The jury returned a verdict in favor of Maiden, and the Court entered a judgment on December 20, 2022. The DSS Defendants filed post-judgment motions seeking reversal of the judgment for several reasons, including that: (1) the evidence does not support Maiden’s claim against the Company; (2) recovery of exemplary damages under TUFTA is unsupported; and (3) the evidence established that the DSS Defendants are entitled to judgment in their favor on their affirmative defenses. After the DSS Defendants filed their post-judgment motions, the case was settled for $8.75 million, the Court’s December 20, 2022 judgment was vacated, and the case was dismissed with prejudice In addition to the foregoing, we may become subject to other legal proceedings that arise in the ordinary course of business and have not been finally adjudicated. Adverse decisions in any of the foregoing may have a material adverse effect on our results of operations, cash flows or our financial condition. The Company accrues for potential litigation losses when a loss is probable and estimable. Contingent Litigation Payments Contingent Payments |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 12 Months Ended |
Dec. 31, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
Supplemental Cash Flow Information | 18. SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Cash Flow Information Supplemental cash flow information for the years ended December 31: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 4,812,000 $ 3,270,000 Non-cash investing and financing activities: Right of use asset $ - $ 9,568,000 Shares issued in lieu of bonus cash $ 268,000 $ 6,221,000 Purchase of notes receivable with company stock $ - $ 8,717,000 Purchase of marketable security with Company stock $ - $ 7,169,000 Third party Note receivable received in lieu of cash $ 1,100,000 - |
Segment Information
Segment Information | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Information | 19. SEGMENT INFORMATION Segment Information The Company’s nine businesses lines are organized, managed, and internally reported as five operating segments. One of these operating segments, Product Packaging, is the Company’s packaging and printing group. Product Packaging operates in the paper board folding carton, smart packaging, and document security printing markets. It markets, manufactures, and sells mailers, photo sleeves, sophisticated custom folding cartons, and complex 3-dimensional direct mail solutions. These products are designed to provide functionality and marketability while also providing counterfeit protection. A second, Biotechnology, invests in, or acquires companies in the biohealth and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Biotechnology is also targeting unmet, urgent medical needs. A third operating segment, Securities and Investment Management (“Securities”) was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Further, Securities, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, stable coins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, STO and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). Also in this segment is the Company’s real estate investment trust (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. The fourth segment, Direct, provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized sharing marketplaces. It specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct marketing products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific and Eastern Europe. The fifth business line, Commercial Banking, is organized for the purposes of being a financial network holding company, focused providing commercial loans and on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy. Our segment structure presented below represents a change from the prior year for the inclusion of our Biotechnology, Securities, and Commercial Lending segments and the removal of our Plastics segment, Digital Group and IP Technology Management segment as the Plastics segment was discontinued in 2020, DSS Digital was sold and discontinued in May 2021 and activities surrounding our IP Technology Management segment have significantly decreased. The amounts for these segments have been included in the Corporate reporting segment for the year ended December 31, 2023 and 2022, as necessary, below for reconciliation purposes. Approximate information concerning the Company’s operations by reportable segment for the twelve months ended December 31, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Year Ended December 31, 2023 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 18,497,000 $ 385,000 $ 6,088,000 $ - $ 5,288,000 $ - $ 30,258,000 Assets held for sale - - - - 51,595,000 - 51,595,000 Depreciation and amortization 761,000 - 157,000 1,163,000 3,047,000 78,000 5,206,000 Cost of revenue 15,282,000 1,139,000 2,075,000 77,000 8,003,000 71,000 26,647,000 Interest expense 185,000 - (5,000 ) - 4,632,000 - 4,812,000 Interest Income - - 986,000 155,000 148,000 - 1,289,000 Stock based compensation - - - - - - - Net income (loss) from continuing operations 327,000 (31,497,000 ) (32,860,000 ) (7,168,000 ) (19,792,000 ) (6,513,000 ) (97,503,000 ) Capital expenditures 689,000 - 4,000 17,000 104,000 4,000 818,000 Identifiable assets 21,508,000 12,285,000 6,303,000 49,305,000 59,345,000 4,446,000 153,192,000 Year Ended December 31,2022 Product Packaging Commercial Lending Direct Biotechnology Securities Corporate Total Revenue $ 17,973,000 $ 764,000 $ 21,989,000 $ - $ 6,581,000 $ - $ 47,307,000 Depreciation and amortization 715,000 - 413,000 1,113,000 9,093,000 129,000 11,463,000 Cost of revenue 16,960,000 1,041,000 9,828,000 - 11,784,000 634,000 40,247,000 Interest expense 140,000 - 1,000 - (15,000 ) - 126,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations (1,234,000 ) (459,000 ) (40,182,000 ) (7,462,000 ) (8,238,000 ) (12,084,000 ) (69,662,000 ) Capital expenditures 1,612,000 - 384,000 276,000 18,000 4,000 2,294,000 Identifiable assets 24,641,000 48,240,000 27,526,000 53,069,000 83,873,000 11,566,000 248,915,000 International revenue, which consists of sales to customers with operations in Canada, Western Europe, Latin America, Africa, the Middle East and Asia comprised 7.0 11.0 The following tables disaggregate our business segment revenues by major source: Printed Products Revenue Information: Schedule of Disaggregation of Revenue Twelve months ended December 31, 2023 Packaging Printing and Fabrication $ 18,036,000 Commercial and Security Printing 461,000 Total Printed Products $ 18,497,000 Twelve months ended December 31, 2022 Packaging Printing and Fabrication $ 17,499,000 Commercial and Security Printing 474,000 Total Printed Products $ 17,973,000 Direct Marketing Twelve months ended December 31, 2023 Direct Marketing Internet Sales $ 6,088,000 Total Direct Marketing $ 6,088,000 Twelve months ended December 31, 2022 Direct Marketing Internet Sales $ 21,989,000 Total Direct Marketing $ 21,989,000 Rental Income Twelve months ended December 31, 2023 Rental income $ 3,647,000 Total Rental Income $ 3,647,000 Twelve months ended December 31, 2022 Rental income $ 6,287,000 Total Rental Income $ 6,287,000 Commission Income Twelve months ended December 31, 2023 Commission income $ 1,641,000 Total commission income $ 1,641,000 Twelve months ended December 31, 2022 Commission income $ 294,000 Total commission income $ 294,000 Management Fee Income Twelve months ended December 31, 2023 Management fee income $ - Total Management fee income $ - Twelve months ended December 31, 2022 Management fee income $ 134,000 Total Management fee income $ 134,000 Net Investment Income Twelve months ended December 31, 2023 Net investment income $ 385,000 Total Net Investment Income $ 385,000 Twelve months ended December 31, 2022 Net investment income $ 630,000 Total Net Investment Income $ 630,000 |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 20. Related Party Transactions The Company owns 127,179,291 4 3,269,000 3,319,000 50,000 1,590,000 On March 2, 2020, AMRE entered into a $ 200,000 8.0 5.00 200,000 On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (“Seller”), a related party, to purchase from the Seller’s its wholly owned subsidiary Impact Oncology PTE Ltd. (“IOPL”) for a purchase price $ 2,480,000 2,480,000 250,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 547,000 3,000,000 On October 13, 2021, LVAM entered into a loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 2,131,000 3,008,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8 matures in December 2023 8,805,000 21,366,177 8,350,000 119,000 677,000 346,000 On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On July 26, 2022, APB and Borrower 11 entered into a promissory note (“Note 11”) in the principal sum of $ 1,000,000 8 July 26, 2024 939,000 20,000 924,000 66,000 In October 2017, Sharing Services issued a Convertible Promissory Note in the principal amount of $ 50,000 333,333 333,333 0.15 78,635.62 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.34 On August 29, 2022, DSS Financial Management Inc and Borrower 10, a related party, entered into a promissory note (“Note 10”) in the principal sum of $ 100,000 8 August 29, 2025 100,000 100,000 76,000 24,000 |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | 21. SUBSEQUENT EVENTS Subsequent Events The Company has evaluated all subsequent events and transactions through March 26, 2024, the date that the consolidated financial statements were available to be issued and other then the reverse stock split identified in Note 14 and noted no subsequent events requiring financial statement recognition or disclosure. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | Principles of Consolidation Deconsolidation of Sharing Services Global Corporation - 280 7% 81% s a result, SHRG, whose operations represented a significant portion of our Direct Marketing segment, was deconsolidated from our consolidated financial statements effective as of May 1, 2023 (the “Deconsolidation”). Subsequent to April 30, 2023, the assets and liabilities of SHRG are no longer included within our consolidated balance sheets. Any discussions related to results, operations, and accounting policies associated with SHRG refer to the periods prior to the Deconsolidation. Upon Deconsolidation, we recognized a loss before income taxes of approximately $ 29,196,000 74,000 |
Use of Estimates | Use of Estimates |
Reclassifications | Reclassifications |
Cash Equivalents | Cash Equivalents |
Accounts Receivable | Accounts Receivable At December 31, 2023, and December 31, 2022, the Company established a reserve for credit losses of approximately $ 2,494,000 29,000 5,673,000 7,564,000 3,994,000 |
Concentration of Credit Risk | Concentration of Credit Risk 14% 6% 36% 17% 20% 11% 39% 30% |
Notes receivable, unearned interest, and related recognition | Notes receivable, unearned interest, and related recognition |
Allowance For Loans And Lease Losses | Allowance For Loans And Lease Losses ASU No.2016-13 – Credit Losses” |
Investments | Investments |
Fair Value of Financial Instruments | Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. |
Inventory | Inventory adjust the inventory balance for obsolete and slow-moving items. An allowance for obsolescence of approximately $ 18,000 and $ 57,000 associated with the inventory at our Premier subsidiary for December 31, 2023 and 2022, respectively. Also, SHRG had an allowance for obsolescence of approximately $ 685,000 |
Property, Plant and Equipment | Property, Plant and Equipment |
Investments in real estate, net | Investments in real estate, net |
Leases | Leases The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period incurred. The Company has elected to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities. |
Impairment of Long-Lived Assets and Goodwill | Impairment of Long-Lived Assets and Goodwill |
Assets held for sale | Assets held for sale – The Company has several buildings and the associated land they occupy for sale as of December 31, 2023. These consist of primarily of retail space in Lindon, Utah approximating $ 5,593,000 41,541,000 4,396,000 65,000 |
Goodwill | Goodwill 1,769,000 25,093,000 APB, and Sentinel Co. of approximately $ 29,744,000 , and $ 1,234,000 respectively, were deemed impaired and written off at December 31, 2023. |
Intangible Assets | Intangible Assets 7,418,000 |
Revenue | Revenue As of December 31, 2023, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. |
Costs of revenue | Costs of revenue - |
Shipping and Handling Costs | Shipping and Handling Costs |
Share-Based Payments | Share-Based Payments |
Sales Commissions | Sales Commissions no |
Contingent Legal Expenses | Contingent Legal Expenses - |
Research and Development | Research and Development 1,147,000 1,256,000 |
Income Taxes | Income Taxes |
Loss Per Common Share | Loss Per Common Share 5,000 For the year-ended December 31, 2023, potential dilutive instruments 0 |
Acquisitions | Acquisitions Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are expensed as incurred. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. |
Business Combinations | Business Combinations |
Continuing Operations and Going Concern | Continuing Operations and Going Concern - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. While the Company has approximately $ 6.6 Aside from its $ 6.6 million in cash as of December 31, 2023, the Company believes it can continue as a going concern, due to its ability to generate operating cash through the sale of its $ 10.0 million of Marketable Securities, and the anticipated receipts of principal and interest on its Notes receivable of approximately $ 8.8 million through December 31, 2024. The Company has also taken steps to sell its real estate holdings in Utah, Texas, Pennsylvania, and Florida. These properties approximate $ 51.6 |
Inventory (Tables)
Inventory (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory | Inventory consisted of the following as of December 31: Schedule of Inventory 2023 2022 Finished Goods $ 2,218,000 $ 6,779,000 Work in Process 180,000 403,000 Raw Materials 439,000 1,281,000 Inventory Gross $ 2,837,000 $ 8,463,000 Less allowance for obsolescence (18,000 ) (742,000 ) Inventory Net $ 2,819,000 $ 7,721,000 |
Provision for Credit Losses (Ta
Provision for Credit Losses (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Provision For Credit Losses | |
Schedule of Loan Loss Reserve | The following table identifies the loan loss reserve for the period ending December 31, : Schedule of Loan Loss Reserve 2023 2022 General Loan Portfolio Reserve $ 194,000 $ 145,000 Specific Loan Reserves $ 5,916,000 $ 896,000 Total $ 6,110,000 $ 1,041,000 |
Schedule of Allowance for Doubtful Accounts and Loan Loss Reserve | Changes in the allowance for doubtful accounts and loan loss reserve were as follows: Schedule of Allowance for Doubtful Accounts and Loan Loss Reserve Allowance for credit losses Loan loss reserve Total Balance at January 1, 2022 $ 20,000 $ - $ 20,000 Adoption of CECL - 1,041,000 1,041,000 Bad debt expense 9,000 - 9,000 Write-offs - - - Recoveries - - - Balance at December 31, 2022 29,000 1,041,000 1,070,000 Bad debt expense 2,000 5,069,000 5,071,000 Write-offs 3,500,000 - 3,500,000 Recoveries (1,037,000 ) - (1,037,000 ) Balance at December 31, 2023 $ 2,494,000 $ 6,110,000 $ 8,604,000 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Investments, All Other Investments [Abstract] | |
Schedule of Cash and Marketable Securities by Significant Investment Category | The following tables show the Company’s cash and marketable securities by significant investment category as of December 31: Schedule of Cash and Marketable Securities by Significant Investment Category 2023 Cost Unrealized Gain/Loss Fair Value Cash And Cash Equivalents Marketable Securities Cash $ 6,545,000 $ - $ 6,545,000 $ 6,545,000 $ - Level 1 Money Market Funds 70,000 - 70,000 70,000 - Marketable Securities 27,304,000 (17,325,000 ) 9,979,000 - 9,979,000 Total $ 33,919,000 $ (17,325,000 ) $ 16,594,000 $ 6,615,000 $ 9,979,000 2022 Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investment Cash $ 19,226,000 $ - $ 19,226,000 $ 19,226,000 $ - $ - Level 1 Money Market Funds 64,000 - 64,000 64,000 - - Marketable Securities 45,283,000 (17,976,000 ) 27,307,000 - 27,307,000 - Level 2 Warrants 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities 1,023,000 - 1,023,000 - - 1,023,000 Total $ 68,914,000 $ (17,976,000 ) $ 50,938,000 $ 19,290,000 $ 27,307,000 $ 4,341,000 |
Schedule of Net Unrealized (Loss) Gain Recognized on marketable Securities | The following tables shows the Company’s net unrealized (loss) gain recognized during the year on marketable securities still held as of December 31: Schedule of Net Unrealized (Loss) Gain Recognized on marketable Securities 2023 2022 Net gains (losses) recognized during the year on marketable securities $ (5,521,000 ) $ (2,757,000 ) Less: Net gains (losses) realized during the year on marketable securities sold during the period (1,973,000 ) 1,077,000 Net unrealized gain (loss) recognized during the reporting year on marketable securities still held at the reporting date $ (3,548,000 ) $ (3,834,000 ) |
Property Plant and Equipment _2
Property Plant and Equipment and Investment in Real Estate, Net (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Plant and Equipment | Property, plant and equipment consisted of the following as of December 31, 2023: Schedule of Property, Plant and Equipment Estimated Useful Life 2023 2022 Machinery and equipment 5 10 $ 9,974,000 $ 9,170,000 Building and improvements 39 294,000 5,103,000 Land - 1,817,000 Furniture and fixtures 7 432,000 501,000 Software and websites 3 273,000 320,000 Construction in progress 365,000 667,000 Total Cost 11,338,000 17,578,000 Less accumulated depreciation 4,921,000 4,187,000 Property, plant and equipment, net $ 6,417,000 $ 13,391,000 |
Schedule of Investment in Real Estate | Real Estate consisted of the following at December 31: Schedule of Investment in Real Estate Estimated Useful Life 2023 2022 Building and improvements 1 30 $ 5,273,000 $ 42,665,000 Land 1,600,000 14,861,000 Total Cost 6,873,000 57,526,000 Less: accumulated depreciation 594,000 2,497,000 Investment in real estate $ 6,279,000 $ 55,029,000 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | Intangible assets are comprised of the following as of December 31: Schedule of Intangible Assets 2023 2022 Useful Life Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology assets 20 $ 22,260,000 $ 3,340,000 - 18,920,000 $ 22,260,000 $ 2,226,000 $ 20,034,000 Acquired intangibles customer lists, licenses, non-compete agreements, branding, product formulas, tenant improvements, in-place, favorable and unfavorable leases 1 11 19,245,000 10,613,000 7,418,000 1,214,000 20,023,000 9,397,000 10,626,000 Acquired intangibles patents and patent rights 500,000 500,000 - - 500,000 500,000 - Patent application costs Varied 1,052,000 993,000 - 59,000 1,052,000 972,000 80,000 $ 43,057,000 $ 15,446,000 $ 7,418,000 $ 20,193,000 $ 43,835,000 $ 13,095,000 $ 30,740,000 (1) Patent application costs are amortized over their expected useful life which is generally the remaining legal life of the patent. As of December 31, 2023, the weighted average remaining useful life of these assets in service was approximately 1.7 |
Schedule of Estimated Future Amortization of Intangible Assets | Expected amortization for each of the five succeeding fiscal years is as follows: Schedule of Estimated Future Amortization of Intangible Assets Year Amount 2024 3,012,000 2025 3,009,000 2026 2,869,000 2027 2,869,000 2028 2,860,000 Thereafter 5,574,000 |
Accrued Expenses and Deferred_2
Accrued Expenses and Deferred Revenue (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accrued Expenses And Deferred Revenue | |
Summary of Accrued Expenses and Deferred Revenue | Accrued expenses and deferred revenue consist of the following for the year ended December 31: Summary of Accrued Expenses and Deferred Revenue 2023 2022 Customer deposits $ 222,000 $ 188,000 Deferred revenue - 519,000 Accrued wages 812,000 4,014,000 Settlement liability - 8,974,000 Uncertain tax positions - 926,000 Accrued expenses 1,468,000 4,536,000 Income tax payable - 172,000 Sales tax payable 10,000 12,000 Accrued expenses and deferred revenue $ 2,512,000 $ 19,341,000 |
Short Term and Long-Term Debt (
Short Term and Long-Term Debt (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Notes Payable and Long-term Debt | A summary of scheduled principal payments of long-term debt, not including revolving lines of credit, subsequent to December 31, 2023 are as follows: Schedule of Notes Payable and Long-term Debt Year Amount 2024 $ 47,776,000 2025 859,000 2026 901,000 2027 947,000 2028 1,200,000 Thereafter 3,544,000 Total 55,227,000 |
Lease Liability (Tables)
Lease Liability (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Lease Liability | |
Schedule of Future Minimum Lease Payments | Future minimum lease payments as of December 31, 2023, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2024 956,000 2025 861,000 2026 839,000 2027 808,000 2028 824,000 After 4,913,000 Total lease payments 9,201,000 Less: Imputed Interest (1,598,000 ) Present value of remaining lease payments $ 7,603,000 Current $ 686,000 Noncurrent $ 6,917,000 Weighted-average remaining lease term (years) 14.3 Weighted-average discount rate 4.1 % |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income Tax Provision | The provision (benefit) for income taxes consists of the following: Schedule of Income Tax Provision 2023 2022 Currently payable: Federal $ - $ 15,000 State 4,000 - Foreign - 119,000 Total currently payable 4,000 134,000 Deferred: Federal (5,392,000 ) (14,839,000 ) State (79,000 ) (492,000 ) Foreign (48,000 ) (58,000 ) Total deferred (5,519,000 ) (15,390,000 ) Less: increase in allowance 5,519,000 15,427,000 Net deferred - 38,000 Total income tax loss (benefit) $ 4,000 $ 172,000 |
Schedule of Deferred Tax Assets and Liabilities | Individual components of deferred tax assets and liabilities are as follows: Schedule of Deferred Tax Assets and Liabilities 2023 2022 Deferred tax assets: Net operating loss carry forwards $ 21,496,000 $ 24,975,000 Net operating loss IRC 382 limited 9,634,000 9,634,000 Unrealized loss on securities 4,655,000 5,753,000 Equity issued for services 190,000 190,000 Goodwill and other intangibles 63,000 34,000 Investment in pass-through entity 11,000 11,000 Deferred revenue 176,000 176,000 Operating Lease Liability 1,713,000 1,935,000 Depreciation and amortization 1,000 24,000 Other 2,507,000 696,000 Gross deferred tax assets 40,446,000 33,794,000 Deferred tax liabilities: Goodwill and other intangibles 3,369,000 2,822,000 Depreciation and amortization 614,000 (194,000 ) Right -of-use asset 1,625,000 1,846,000 Gross deferred tax liabilities 5,608,000 4,474,000 Less: valuation allowance (34,838,000 ) (29,357,000 ) Net deferred tax liabilities $ - $ (38,000 ) |
Schedule of Effective Income Tax Rate Reconciliation | The differences between the United States statutory federal income tax rate and the effective income tax rate in the accompanying consolidated statements of operations are as follows: Schedule of Effective Income Tax Rate Reconciliation 2023 2022 Statutory United States federal rate 21.0 % 21.0 % State income taxes net of federal benefit 0.38 % 0.51 % Permanent differences (6.68 )% 0.03 % Other (9.04 )% 0.93 % Foreign taxes - % (0.07 )% Change in valuation allowance (5.66 )% (22.66 )% Effective rate - % (0.25 )% |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Supplemental Cash Flow Information | Supplemental cash flow information for the years ended December 31: Schedule of Supplemental Cash Flow Information 2023 2022 Cash paid for interest $ 4,812,000 $ 3,270,000 Non-cash investing and financing activities: Right of use asset $ - $ 9,568,000 Shares issued in lieu of bonus cash $ 268,000 $ 6,221,000 Purchase of notes receivable with company stock $ - $ 8,717,000 Purchase of marketable security with Company stock $ - $ 7,169,000 Third party Note receivable received in lieu of cash $ 1,100,000 - |
Segment Information (Tables)
Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Operations by Reportable Segment | Approximate information concerning the Company’s operations by reportable segment for the twelve months ended December 31, 2023 and 2022 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Year Ended December 31, 2023 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 18,497,000 $ 385,000 $ 6,088,000 $ - $ 5,288,000 $ - $ 30,258,000 Assets held for sale - - - - 51,595,000 - 51,595,000 Depreciation and amortization 761,000 - 157,000 1,163,000 3,047,000 78,000 5,206,000 Cost of revenue 15,282,000 1,139,000 2,075,000 77,000 8,003,000 71,000 26,647,000 Interest expense 185,000 - (5,000 ) - 4,632,000 - 4,812,000 Interest Income - - 986,000 155,000 148,000 - 1,289,000 Stock based compensation - - - - - - - Net income (loss) from continuing operations 327,000 (31,497,000 ) (32,860,000 ) (7,168,000 ) (19,792,000 ) (6,513,000 ) (97,503,000 ) Capital expenditures 689,000 - 4,000 17,000 104,000 4,000 818,000 Identifiable assets 21,508,000 12,285,000 6,303,000 49,305,000 59,345,000 4,446,000 153,192,000 Year Ended December 31,2022 Product Packaging Commercial Lending Direct Biotechnology Securities Corporate Total Revenue $ 17,973,000 $ 764,000 $ 21,989,000 $ - $ 6,581,000 $ - $ 47,307,000 Depreciation and amortization 715,000 - 413,000 1,113,000 9,093,000 129,000 11,463,000 Cost of revenue 16,960,000 1,041,000 9,828,000 - 11,784,000 634,000 40,247,000 Interest expense 140,000 - 1,000 - (15,000 ) - 126,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations (1,234,000 ) (459,000 ) (40,182,000 ) (7,462,000 ) (8,238,000 ) (12,084,000 ) (69,662,000 ) Capital expenditures 1,612,000 - 384,000 276,000 18,000 4,000 2,294,000 Identifiable assets 24,641,000 48,240,000 27,526,000 53,069,000 83,873,000 11,566,000 248,915,000 |
Schedule of Disaggregation of Revenue | Printed Products Revenue Information: Schedule of Disaggregation of Revenue Twelve months ended December 31, 2023 Packaging Printing and Fabrication $ 18,036,000 Commercial and Security Printing 461,000 Total Printed Products $ 18,497,000 Twelve months ended December 31, 2022 Packaging Printing and Fabrication $ 17,499,000 Commercial and Security Printing 474,000 Total Printed Products $ 17,973,000 Direct Marketing Twelve months ended December 31, 2023 Direct Marketing Internet Sales $ 6,088,000 Total Direct Marketing $ 6,088,000 Twelve months ended December 31, 2022 Direct Marketing Internet Sales $ 21,989,000 Total Direct Marketing $ 21,989,000 Rental Income Twelve months ended December 31, 2023 Rental income $ 3,647,000 Total Rental Income $ 3,647,000 Twelve months ended December 31, 2022 Rental income $ 6,287,000 Total Rental Income $ 6,287,000 Commission Income Twelve months ended December 31, 2023 Commission income $ 1,641,000 Total commission income $ 1,641,000 Twelve months ended December 31, 2022 Commission income $ 294,000 Total commission income $ 294,000 Management Fee Income Twelve months ended December 31, 2023 Management fee income $ - Total Management fee income $ - Twelve months ended December 31, 2022 Management fee income $ 134,000 Total Management fee income $ 134,000 Net Investment Income Twelve months ended December 31, 2023 Net investment income $ 385,000 Total Net Investment Income $ 385,000 Twelve months ended December 31, 2022 Net investment income $ 630,000 Total Net Investment Income $ 630,000 |
Description of Business (Detail
Description of Business (Details Narrative) - USD ($) | 12 Months Ended | ||||||||
May 17, 2022 | May 17, 2022 | Mar. 09, 2022 | Feb. 28, 2022 | Feb. 28, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | May 31, 2023 | May 13, 2021 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Issuance of common stock, net of expenses | $ 268,000 | $ 17,405,000 | |||||||
Stock issued during period shares acquisitions | 17,570,948 | ||||||||
Alset EHome International Inc [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Shares issued for convertible debt | 21,366,177 | 21,366,177 | |||||||
Shares issued for convertible debt, value | $ 8,350,000 | ||||||||
Unpaid interest | $ 367,000 | ||||||||
Sentinel Brokers LLC [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Equity position percentage | 75% | 80.10% | |||||||
Stock Purchase Agreement [Member] | Alset EHome International Inc [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Issuance of common stock, net of expenses, shares | 3,986,877 | 44,619,423 | 44,619,423 | ||||||
Shares issued, price per share | $ 0.3810 | $ 0.3810 | |||||||
Issuance of common stock, net of expenses | $ 1,519,000 | $ 17,000,000 | $ 17,000,000 | ||||||
Sentinel Brokers LLC [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Acquisition percentage | 5% | ||||||||
Sentinel Brokers LLC [Member] | Stock Purchase Agreement [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Acquisition percentage | 24.90% | ||||||||
True Partners Capital Holdings Limited [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Stock issued during period shares acquisitions | 62,122,908 | 62,122,908 | |||||||
Share price | $ 0.34 | $ 0.34 | |||||||
True Partners Capital Holdings Limited [Member] | DSS Inc [Member] | |||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||||
Stock issued during period shares acquisitions | 17,570,948 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 12 Months Ended | |||||
May 04, 2023 | May 04, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | May 03, 2023 | Jan. 01, 2022 | |
Deconsolidation on loss before income taxes | $ 29,196,000 | |||||
Value of marketable securities | $ 10,000,000 | |||||
Reserve for credit losses | 2,494,000 | $ 29,000 | ||||
Accounts receivable net | 3,994,000 | 7,564,000 | $ 5,673,000 | |||
Inventory Adjustments | 18,000 | 742,000 | ||||
Other assets | 65,000 | |||||
Goodwill | 26,862,000 | 60,919,000 | ||||
Asset impairment | 7,418,000 | |||||
Sales commissions | 0 | |||||
Research and development | 1,147,000 | 1,256,000 | ||||
Cash | 6,600,000 | |||||
Convertible Debt | 8,800,000 | |||||
Assets held for sale | $ 51,595,000 | |||||
Warrant [Member] | ||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 5,000 | |||||
Share-Based Payment Arrangement, Option [Member] | ||||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 | |||||
AMRE Life Care Portfolio LLC [Member] | ||||||
Real Estate Assets Held for Development and Sale | $ 41,541,000 | |||||
AMRE Winter Haven LLC [Member] | ||||||
Real Estate Assets Held for Development and Sale | 4,396,000 | |||||
Premier Packaging Corp [Member] | ||||||
Goodwill | 1,769,000 | |||||
Impact BioMedical, Inc. [Member] | ||||||
Goodwill | 25,093,000 | |||||
American Pacific Bancorp [Member] | ||||||
Goodwill | 29,744,000 | |||||
Sentinel Brokers Company Inc [Member] | ||||||
Goodwill | 1,234,000 | |||||
UTAH | ||||||
Real Estate Assets Held for Development and Sale | 5,593,000 | |||||
Premier Subsidiary [Member] | ||||||
Inventory Adjustments | $ 18,000 | $ 57,000 | ||||
SHRG Subsidiary [Member] | ||||||
Inventory Adjustments | $ 685,000 | |||||
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||||||
Concentration risk, percentage | 20% | 14% | ||||
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | ||||||
Concentration risk, percentage | 39% | 36% | ||||
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||||||
Concentration risk, percentage | 11% | 6% | ||||
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | ||||||
Concentration risk, percentage | 30% | 17% | ||||
Sharing Services Global Corp [Member] | ||||||
Number of shares issued | 280,000,000 | |||||
Ownership interest percentage | 7% | 7% | ||||
Percentage of issued and outstanding | 81% | |||||
Value of marketable securities | $ 74,000 |
Schedule of Inventory (Details)
Schedule of Inventory (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Inventory Disclosure [Abstract] | ||
Finished Goods | $ 2,218,000 | $ 6,779,000 |
Work in Process | 180,000 | 403,000 |
Raw Materials | 439,000 | 1,281,000 |
Inventory Gross | 2,837,000 | 8,463,000 |
Less allowance for obsolescence | (18,000) | (742,000) |
Inventory Net | $ 2,819,000 | $ 7,721,000 |
Notes Receivable (Details Narra
Notes Receivable (Details Narrative) - USD ($) | 12 Months Ended | ||||||||||||||||||||
Sep. 28, 2023 | Jun. 27, 2023 | May 08, 2023 | Mar. 31, 2023 | Dec. 29, 2022 | Aug. 29, 2022 | Aug. 11, 2022 | Jul. 26, 2022 | Jun. 15, 2022 | May 09, 2022 | Mar. 02, 2022 | Jan. 24, 2022 | Dec. 28, 2021 | Oct. 25, 2021 | Sep. 23, 2021 | May 14, 2021 | Feb. 19, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Nov. 27, 2023 | Aug. 31, 2023 | |
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Notes receivable current | $ 8,772,000 | $ 11,719,000 | |||||||||||||||||||
Principal and interest outstanding | 8,800,000 | ||||||||||||||||||||
Notes receivable net non-current | $ 111,000 | $ 922,000 | |||||||||||||||||||
Preferred stock, par value | $ 0.02 | $ 0.02 | |||||||||||||||||||
Long term debt current | $ 47,776,000 | $ 47,161,000 | |||||||||||||||||||
Long term debt | $ 55,227,000 | ||||||||||||||||||||
Note 12 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt exchanged for shares | 26,000 | ||||||||||||||||||||
Preferred stock, par value | $ 0.0001 | ||||||||||||||||||||
Redeemable preferred stoc, per share | $ 1,000 | ||||||||||||||||||||
Note 1 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 5,000,000 | ||||||||||||||||||||
Debt instrument interest rate | 6.65% | ||||||||||||||||||||
Debt instrument maturity date | May 01, 2023 | ||||||||||||||||||||
Debt conversion description | Note 1 contains an optional conversion clause that allows the Company to convert all, or a portion of all, into newly issued member units of Borrower 1 with the maximum principal amount equal to 18% of the total equity position of Borrower 1 at conversion | ||||||||||||||||||||
Notes receivable current | $ 5,544,000 | 5,420,000 | |||||||||||||||||||
Principal and interest outstanding | 2,772,000 | ||||||||||||||||||||
Note 2 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 3,500,000 | ||||||||||||||||||||
Debt instrument interest rate | 5.59% | ||||||||||||||||||||
Debt instrument maturity date | Sep. 22, 2022 | ||||||||||||||||||||
Notes receivable current | 3,910,000 | 3,701,000 | |||||||||||||||||||
Extended maturity date | Sep. 19, 2024 | ||||||||||||||||||||
Note 3 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||
Debt instrument maturity date | Oct. 25, 2022 | ||||||||||||||||||||
Notes receivable current | 884,000 | ||||||||||||||||||||
Line of credit facility, maximum borrowing capacity | $ 3,000,000 | ||||||||||||||||||||
Debt description | This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest. | ||||||||||||||||||||
Note 3 [Member] | Maximum [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 1,000,000 | ||||||||||||||||||||
Note 4 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument interest rate | 12.50% | ||||||||||||||||||||
Debt instrument maturity date | May 15, 2023 | ||||||||||||||||||||
Note 4 [Member] | Promissory Note One [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 250,000 | ||||||||||||||||||||
Notes receivable net non-current | 252,000 | ||||||||||||||||||||
Note 4 [Member] | Promissory Note Two [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 10,000 | ||||||||||||||||||||
Notes receivable net non-current | 9,000 | ||||||||||||||||||||
Note 5 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Notes receivable current | 0 | 63,000 | |||||||||||||||||||
Note 6 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 700,000 | ||||||||||||||||||||
Debt instrument interest rate | 12% | ||||||||||||||||||||
Debt instrument maturity date | Dec. 28, 2022 | ||||||||||||||||||||
Notes receivable current | 253,000 | 701,000 | $ 50,000 | ||||||||||||||||||
Extended maturity date | May 31, 2023 | ||||||||||||||||||||
Note 7 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 100,000 | ||||||||||||||||||||
Debt instrument interest rate | 6% | ||||||||||||||||||||
Notes receivable net non-current | 103,000 | 106,000 | |||||||||||||||||||
Note 8 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 893,000 | ||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||
Debt instrument, face amount | March 2024 | January 2024 | |||||||||||||||||||
Notes and loans receivable gross current | 446,000 | 874,000 | |||||||||||||||||||
Unamortized origination fees | 3,500 | 25,000 | |||||||||||||||||||
Note 9 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 210,000 | ||||||||||||||||||||
Debt instrument interest rate | 10% | ||||||||||||||||||||
Debt instrument maturity date | Feb. 09, 2023 | ||||||||||||||||||||
Notes receivable current | 224,000 | ||||||||||||||||||||
Notes and loans receivable gross current | 213,000 | ||||||||||||||||||||
Notes receivable current reserved | 112,000 | ||||||||||||||||||||
Note 10 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 100,000 | ||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||
Debt instrument maturity date | Aug. 29, 2025 | ||||||||||||||||||||
Notes receivable current | 24,000 | 76,000 | |||||||||||||||||||
Notes and loans receivable gross current | $ 100,000 | 100,000 | |||||||||||||||||||
Note 10 [Member] | Borrower Ten [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Ownership percentage | 24.90% | ||||||||||||||||||||
Note 11 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 100,000 | $ 1,000,000 | |||||||||||||||||||
Debt instrument interest rate | 8% | 8% | |||||||||||||||||||
Debt instrument maturity date | Aug. 29, 2025 | Jul. 26, 2024 | |||||||||||||||||||
Notes receivable current | $ 24,000 | 76,000 | |||||||||||||||||||
Notes and loans receivable gross current | 939,000 | 924,000 | |||||||||||||||||||
Unamortized origination fees | 20,000 | 66,000 | |||||||||||||||||||
Note 12 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 27,000,000 | ||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||
Debt instrument maturity date | Jun. 14, 2024 | ||||||||||||||||||||
Conversion price | $ 0.03 | ||||||||||||||||||||
Note 13 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 206,000 | ||||||||||||||||||||
Debt instrument interest rate | 6.50% | ||||||||||||||||||||
Debt instrument maturity date | Aug. 19, 2022 | ||||||||||||||||||||
Notes receivable current | 206,000 | ||||||||||||||||||||
Notes receivable net non-current | 190,000 | ||||||||||||||||||||
Notes and loans receivable gross current | 203,000 | $ 16,000 | |||||||||||||||||||
Note 14 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 102,000 | ||||||||||||||||||||
Debt instrument interest rate | 2% | ||||||||||||||||||||
Debt instrument maturity date | May 07, 2026 | ||||||||||||||||||||
Notes receivable current | 54,000 | ||||||||||||||||||||
Notes and loans receivable gross current | $ 107,000 | ||||||||||||||||||||
Effective rate percentage | 10.50% | ||||||||||||||||||||
Long term debt current | $ 53,000 | ||||||||||||||||||||
Note 15 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 1,400,000 | ||||||||||||||||||||
Debt instrument interest rate | 10% | ||||||||||||||||||||
Debt instrument maturity date | Sep. 01, 2024 | ||||||||||||||||||||
Debt instrument, unamortized discount | $ 300,000 | ||||||||||||||||||||
Note Sixteen [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 140,000 | ||||||||||||||||||||
Debt instrument interest rate | 8.50% | ||||||||||||||||||||
Debt instrument maturity date | Mar. 31, 2025 | ||||||||||||||||||||
Notes and loans receivable gross current | 133,000 | ||||||||||||||||||||
Long term debt current | 99,000 | ||||||||||||||||||||
Long term debt | 34,000 | ||||||||||||||||||||
Note 17 [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 400,000 | ||||||||||||||||||||
Debt instrument interest rate | 5% | ||||||||||||||||||||
Debt instrument maturity date | Nov. 12, 2023 | ||||||||||||||||||||
Note Eighteen [Member] | |||||||||||||||||||||
Financing Receivable, Modified [Line Items] | |||||||||||||||||||||
Debt instrument face amount | $ 1,430,000 | ||||||||||||||||||||
Debt instrument interest rate | 8% | ||||||||||||||||||||
Debt instrument maturity date | Aug. 12, 2024 | ||||||||||||||||||||
Notes and loans receivable gross current | 1,102,000 | ||||||||||||||||||||
Unamortized origination fees | $ 375,000 |
Schedule of Loan Loss Reserve (
Schedule of Loan Loss Reserve (Details) - American Pacific Bancorp [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
General Loan Portfolio Reserve [Member] | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Total | $ 194,000 | $ 145,000 |
Nonperforming Financial Instruments [Member] | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Total | 6,110,000 | 1,041,000 |
Nonperforming Financial Instruments [Member] | General Loan Portfolio Reserve [Member] | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Total | 194,000 | 145,000 |
Nonperforming Financial Instruments [Member] | Specific Loan Reserves [Member] | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Total | $ 5,916,000 | $ 896,000 |
Schedule of Allowance for Doubt
Schedule of Allowance for Doubtful Accounts and Loan Loss Reserve (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Provision For Credit Losses | ||
Allowance for doubtful accounts, Balance | $ 29,000 | $ 20,000 |
Loan loss reserve, Balance | 1,041,000 | |
Allowance for doubtful accounts and loan loss reserve, Balance | 1,070,000 | 20,000 |
Allowance for doubtful accounts, Adoption of CECL | ||
Loan loss reserve, Adoption of CECL | 1,041,000 | |
Allowance for doubtful accounts and loan loss reserve, Adoption of CECL | 1,041,000 | |
Allowance for doubtful accounts, Bad debt expense | 2,000 | 9,000 |
Loan loss reserve, Bad debt expense | 5,069,000 | |
Allowance for doubtful accounts and loan loss reserve, Bad debt expense | 5,071,000 | 9,000 |
Allowance for doubtful accounts, Write offs | 3,500,000 | |
Loan loss reserve, Write offs | ||
Allowance for doubtful accounts and loan loss reserve, Write offs | 3,500,000 | |
Allowance for doubtful accounts, Recoveries | (1,037,000) | |
Loan loss reserve, Recoveries | ||
Allowance for doubtful accounts and loan loss reserve, Recoveries | (1,037,000) | |
Allowance for doubtful accounts, Balance | 2,494,000 | 29,000 |
Loan loss reserve, Balance | 6,110,000 | 1,041,000 |
Allowance for doubtful accounts and loan loss reserve, Balance | $ 8,604,000 | $ 1,070,000 |
Provision for Credit Losses (De
Provision for Credit Losses (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Financing Receivable, Past Due [Line Items] | ||
Outstanding principal and interest | $ 8,800,000 | |
General Loan Portfolio Reserve [Member] | American Pacific Bancorp [Member] | ||
Financing Receivable, Past Due [Line Items] | ||
Portfolio reserve | 194,000 | $ 145,000 |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | Borrower 4 [Member] | ||
Financing Receivable, Past Due [Line Items] | ||
Current nonaccrual loan balance | 884,000 | |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | Borrower 2 [Member] | ||
Financing Receivable, Past Due [Line Items] | ||
Outstanding principal and interest | 2,884,000 | |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | Borrower 16 [Member] | ||
Financing Receivable, Past Due [Line Items] | ||
Outstanding principal and interest | 1,046,000 | |
Specific Loan Reserves [Member] | American Pacific Bancorp [Member] | Asili LLC [Member] | Borrower 19 [Member] | ||
Financing Receivable, Past Due [Line Items] | ||
Outstanding principal and interest | 1,102,000 | |
Loan [Member] | ||
Financing Receivable, Past Due [Line Items] | ||
Portfolio loan incurred | $ 4,933,000 | $ 1,041,000 |
Schedule of Cash and Marketable
Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | |
Cash and Cash Equivalents [Line Items] | |||
Cost | $ 33,919,000 | $ 68,914,000 | |
Unrealized Gain/(Loss) | (17,325,000) | (17,976,000) | |
Fair Value | 16,594,000 | 50,938,000 | |
Cash and Cash Equivalents | 6,615,000 | 19,290,000 | |
Current marketable securities | 9,979,000 | 27,307,000 | |
Investments | 4,341,000 | ||
Fair Value, Inputs, Level 2 [Member] | Convertible Securities [Member] | |||
Cash and Cash Equivalents [Line Items] | |||
Cost | 1,023,000 | ||
Unrealized Gain/(Loss) | |||
Fair Value | 1,023,000 | ||
Cash and Cash Equivalents | |||
Current marketable securities | |||
Investments | 1,023,000 | ||
Fair Value, Inputs, Level 2 [Member] | Warrant [Member] | |||
Cash and Cash Equivalents [Line Items] | |||
Cost | 3,318,000 | ||
Unrealized Gain/(Loss) | |||
Fair Value | 3,318,000 | ||
Cash and Cash Equivalents | |||
Current marketable securities | |||
Investments | 3,318,000 | ||
Cash [Member] | |||
Cash and Cash Equivalents [Line Items] | |||
Cost | 6,545,000 | 19,226,000 | |
Unrealized Gain/(Loss) | |||
Fair Value | 6,545,000 | 19,226,000 | |
Cash and Cash Equivalents | 6,545,000 | 19,226,000 | |
Current marketable securities | |||
Investments | |||
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | |||
Cash and Cash Equivalents [Line Items] | |||
Cost | 70,000 | 64,000 | |
Unrealized Gain/(Loss) | |||
Fair Value | 70,000 | 64,000 | |
Cash and Cash Equivalents | 70,000 | 64,000 | |
Current marketable securities | |||
Investments | |||
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member] | |||
Cash and Cash Equivalents [Line Items] | |||
Cost | 27,304,000 | 45,283,000 | |
Unrealized Gain/(Loss) | (17,325,000) | (17,976,000) | |
Fair Value | 9,979,000 | 27,307,000 | |
Cash and Cash Equivalents | |||
Current marketable securities | $ 9,979,000 | 27,307,000 | |
Investments |
Schedule of Net Unrealized (Los
Schedule of Net Unrealized (Loss) Gain Recognized on marketable Securities (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Investments, All Other Investments [Abstract] | ||
Net gains (losses) recognized during the year on marketable securities | $ (5,521,000) | $ (2,757,000) |
Less: Net gains (losses) realized during the year on marketable securities sold during the period | (1,973,000) | 1,077,000 |
Net unrealized gain (loss) recognized during the reporting year on marketable securities still held at the reporting date | $ (3,548,000) | $ (3,834,000) |
Disposal of Assets (Details Nar
Disposal of Assets (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Jul. 01, 2023 | Sep. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | |
Proceeds from sale of inventory | $ 1,519,000 | |||
Net loss | $ (80,606,000) | $ (59,840,000) | ||
HWH World Inc [Member] | ||||
Equity percentage | 100% | |||
Sharing Services Global Corporation [Member] | Amended Agreement [Member] | ||||
Proceeds from sale of inventory | $ 758,000 | |||
Proceeds from sale of inventory | 698,000 | |||
Liabilities assumed | 59,000 | |||
Agreement description | the agreement includes payment of 1% royalty, starting November 1, 2023, being defined as 1% of the gross sale price of all Seller’s new products made and sold outside of existing inventory on the schedule, for a period ending October 31, 2033. | |||
Net loss | $ 639,000 | |||
HWH World Inc [Member] | ||||
Net loss | 617,000 | |||
Purchase price consideration | $ 2,590 | |||
HWH World Inc [Member] | Sharing Services Global Corporation [Member] | ||||
Sale of stock, number of shares issued in transaction | 1,000 | |||
Sale of stock, consideration received per transaction | $ 706,000 |
Investments (Details Narrative)
Investments (Details Narrative) - USD ($) | 1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||
Jul. 22, 2021 | Apr. 01, 2021 | Mar. 18, 2021 | Mar. 18, 2021 | Mar. 15, 2021 | Dec. 30, 2020 | Dec. 19, 2020 | Sep. 10, 2020 | Sep. 30, 2021 | Sep. 30, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | |
Marketable securities | $ 10,000,000 | |||||||||||||
Unrealized gain loss on investments | (17,325,000) | $ (17,976,000) | ||||||||||||
Investments | 4,341,000 | |||||||||||||
Issuance of common stock, net of expenses | 268,000 | 17,405,000 | ||||||||||||
Proceeds from Issuance of common stock | 1,519,000 | |||||||||||||
Vivacitas Agreement [Member] | ||||||||||||||
Stock options exercised | 1,000,000 | |||||||||||||
Stock options exercised price | $ 1,000,000 | |||||||||||||
Investment owned at cost | $ 4,100,000 | $ 4,035,000 | ||||||||||||
Investment ownership percentage | 100% | 100% | ||||||||||||
Common Stock [Member] | ||||||||||||||
Issuance of common stock, net of expenses | $ 1 | $ 43,000 | ||||||||||||
Issuance of common stock, net of expenses, shares | 62,354 | 2,146,200 | ||||||||||||
BMI Capital International LLC [Member] | ||||||||||||||
Issuance of common stock, net of expenses | $ 100,000 | |||||||||||||
Investments equity method | $ 34,000 | $ 20,000 | ||||||||||||
Impact Oncology PTE Ltd. [Member] | ||||||||||||||
Owners shares | 2,480,000 | 2,480,000 | ||||||||||||
Options to purchase additional shares | 250,000 | |||||||||||||
Business combination consideration transferred | $ 2,480,000 | $ 2,480,000 | ||||||||||||
Stemtech Corporation [Member] | Securities Purchase Agreement [Member] | ||||||||||||||
Investments | $ 1,400,000 | $ 1,400,000 | ||||||||||||
Business combination consideration transferred | 1,400,000 | |||||||||||||
Convertible promissory note | $ 1,400,000 | 1,400,000 | ||||||||||||
Origination fee | $ 500,000 | |||||||||||||
Maturity date | Sep. 09, 2024 | |||||||||||||
Interest rate | 10% | 10% | ||||||||||||
Stockholders equity | 154,173 | |||||||||||||
Warrant outstanding | 0 | 0 | ||||||||||||
Note payable | $ 44,000 | $ 39,000 | ||||||||||||
DSS Securities, Inc. [Member] | ||||||||||||||
Equity position percentage | 14.90% | |||||||||||||
BMI Capital International LLC [Member] | ||||||||||||||
Equity position percentage | 24.90% | |||||||||||||
BMI Capital International LLC [Member] | Minimum [Member] | ||||||||||||||
Equity position percentage | 20% | |||||||||||||
BioMed Technologies Asia Pacific Holdings Limited [Member] | ||||||||||||||
Equity position percentage | 4.99% | |||||||||||||
Issuance of common stock, net of expenses | $ 632,000 | |||||||||||||
Issuance of common stock, net of expenses, shares | 525 | |||||||||||||
Vivacitas Oncology Inc [Member] | Vivacitas Agreement [Member] | ||||||||||||||
Equity position percentage | 16% | |||||||||||||
Moji Life LLC [Member] | Membership Unit Purchase Agreement [Member] | ||||||||||||||
Equity position percentage | 30.75% | 30.75% | ||||||||||||
Payments to Acquire Equity Method Investments | $ 1,537,000 | |||||||||||||
Alset International Limited [Member] | ||||||||||||||
Owners shares | 127,179,291 | |||||||||||||
Outstanding share percentage | 4% | |||||||||||||
Marketable securities | $ 3,269,000 | $ 3,319,000 | ||||||||||||
Unrealized gain loss on investments | 50,000 | 1,590,000 | ||||||||||||
Alset International Limited [Member] | Executive Director and Chief Executive Officer [Member] | ||||||||||||||
Unrealized gain loss on investments | 50,000 | 1,590,000 | ||||||||||||
West Park Capital, Inc [Member] | ||||||||||||||
Debt instrument convertible threshold percentage of stock price trigger | 7.50% | |||||||||||||
Investments | $ 500,000 | $ 500,000 | ||||||||||||
DSS Securities, Inc. [Member] | ||||||||||||||
Issuance of common stock, net of expenses | $ 100,000 | |||||||||||||
Outstanding membership interest | 10% | |||||||||||||
Vivacitas Oncology Inc [Member] | ||||||||||||||
Options to purchase additional shares | 1,500,000 | |||||||||||||
Shares issued, price per share | $ 1 | |||||||||||||
Additional price per share | $ 1 | |||||||||||||
Proceeds from Issuance of common stock | $ 500,000 | |||||||||||||
Business combination consideration transferred | $ 120,000 | |||||||||||||
Sale of stock, description | the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022 | |||||||||||||
Share Price | $ 1 | |||||||||||||
Vivacitas Oncology Inc [Member] | Common Stock [Member] | ||||||||||||||
Options to purchase additional shares | 500,000 |
Schedule of Property, Plant and
Schedule of Property, Plant and Equipment (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Total Cost | $ 11,338,000 | $ 17,578,000 |
Less accumulated depreciation | 4,921,000 | 4,187,000 |
Property, plant and equipment, net | 6,417,000 | 13,391,000 |
Machinery and Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Cost | $ 9,974,000 | 9,170,000 |
Machinery and Equipment [Member] | Minimum [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, useful life | 5 years | |
Machinery and Equipment [Member] | Maximum [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, useful life | 10 years | |
Building and Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Cost | $ 294,000 | 5,103,000 |
Property, plant and equipment, useful life | 39 years | |
Land [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Cost | 1,817,000 | |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Cost | $ 432,000 | 501,000 |
Property, plant and equipment, useful life | 7 years | |
Computer Software, Intangible Asset [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Cost | $ 273,000 | 320,000 |
Property, plant and equipment, useful life | 3 years | |
Construction in Progress [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Cost | $ 365,000 | $ 667,000 |
Schedule of Investment in Real
Schedule of Investment in Real Estate (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Investment in real estate | $ 6,279,000 | $ 55,029,000 |
Total Cost | 6,873,000 | 57,526,000 |
Less: accumulated depreciation | 594,000 | 2,497,000 |
Building and Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Investment in real estate | $ 5,273,000 | 42,665,000 |
Building and Improvements [Member] | Minimum [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, useful life | 1 year | |
Building and Improvements [Member] | Maximum [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, useful life | 30 years | |
Land [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Investment in real estate | $ 1,600,000 | $ 14,861,000 |
Property Plant and Equipment _3
Property Plant and Equipment and Investment in Real Estate, Net (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 802,000 | $ 1,569,000 |
Depreciation of real estate | $ 2,085,000 | $ 2,077,000 |
Schedule of Intangible Assets (
Schedule of Intangible Assets (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | ||
Finite-Lived Intangible Assets [Line Items] | |||
Gross Carrying Amount | $ 43,057,000 | $ 43,835,000 | |
Accumulated Amortization | 15,446,000 | 13,095,000 | |
Impairment | 7,418,000 | ||
Net Carrying Amount | $ 20,193,000 | 30,740,000 | |
Developed Technology Assets [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Useful Life | 20 years | ||
Gross Carrying Amount | $ 22,260,000 | 22,260,000 | |
Accumulated Amortization | 3,340,000 | 2,226,000 | |
Impairment | |||
Net Carrying Amount | 18,920,000 | 20,034,000 | |
Acquired Intangibles Customer Lists,Llicenses, Non-Compete Agreements, Branding, Product Formulas, Tenant Improvements, In-place, Favorable and Unfavorable Leases [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross Carrying Amount | 19,245,000 | 20,023,000 | |
Accumulated Amortization | 10,613,000 | 9,397,000 | |
Impairment | 7,418,000 | ||
Net Carrying Amount | $ 1,214,000 | 10,626,000 | |
Acquired Intangibles Customer Lists,Llicenses, Non-Compete Agreements, Branding, Product Formulas, Tenant Improvements, In-place, Favorable and Unfavorable Leases [Member] | Minimum [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Useful Life | 1 year | ||
Acquired Intangibles Customer Lists,Llicenses, Non-Compete Agreements, Branding, Product Formulas, Tenant Improvements, In-place, Favorable and Unfavorable Leases [Member] | Maximum [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Useful Life | 11 years | ||
Acquired Intangibles Patents and Patent Rights [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross Carrying Amount | $ 500,000 | 500,000 | |
Accumulated Amortization | 500,000 | 500,000 | |
Impairment | |||
Net Carrying Amount | |||
Patents [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Gross Carrying Amount | 1,052,000 | 1,052,000 | |
Accumulated Amortization | 993,000 | 972,000 | |
Impairment | |||
Net Carrying Amount | $ 59,000 | $ 80,000 | |
Useful life, description | [1] | Varied | |
[1]Patent application costs are amortized over their expected useful life which is generally the remaining legal life of the patent. As of December 31, 2023, the weighted average remaining useful life of these assets in service was approximately 1.7 |
Schedule of Intangible Assets_2
Schedule of Intangible Assets (Details) (Parenthetical) | 12 Months Ended |
Dec. 31, 2023 | |
Patents [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Weighted average remaining useful life | 1 year 8 months 12 days |
Schedule of Estimated Future Am
Schedule of Estimated Future Amortization of Intangible Assets (Details) | Dec. 31, 2023 USD ($) |
Goodwill and Intangible Assets Disclosure [Abstract] | |
2024 | $ 3,012,000 |
2025 | 3,009,000 |
2026 | 2,869,000 |
2027 | 2,869,000 |
2028 | 2,860,000 |
Thereafter | $ 5,574,000 |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) - USD ($) | 12 Months Ended | ||
Aug. 25, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Finite-Lived Intangible Assets [Line Items] | |||
Payments to acquire intangible assets | $ 508,000 | ||
Related intangible assets | 20,193,000 | 30,740,000 | |
Amortization of intangible assets | 2,319,000 | $ 9,279,000 | |
Asset Purchase Agreement [Member] | Celios Corporation [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Payments to acquire intangible assets | $ 900,000 | ||
Related intangible assets | $ 409,000 | ||
Asset Purchase Agreement [Member] | Celios Corporation [Member] | Minimum [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible asset, estimated remaining useful life | 3 years | ||
Asset Purchase Agreement [Member] | Celios Corporation [Member] | Maximum [Member] | |||
Finite-Lived Intangible Assets [Line Items] | |||
Intangible asset, estimated remaining useful life | 20 years |
Summary of Accrued Expenses and
Summary of Accrued Expenses and Deferred Revenue (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Accrued Expenses And Deferred Revenue | ||
Customer deposits | $ 222,000 | $ 188,000 |
Deferred revenue | 519,000 | |
Accrued wages | 812,000 | 4,014,000 |
Settlement liability | 8,974,000 | |
Uncertain tax positions | 926,000 | |
Accrued expenses | 1,468,000 | 4,536,000 |
Income tax payable | 172,000 | |
Sales tax payable | 10,000 | 12,000 |
Accrued expenses and deferred revenue | $ 2,512,000 | $ 19,341,000 |
Schedule of Notes Payable and L
Schedule of Notes Payable and Long-term Debt (Details) | Dec. 31, 2023 USD ($) |
Debt Disclosure [Abstract] | |
2024 | $ 47,776,000 |
2025 | 859,000 |
2026 | 901,000 |
2027 | 947,000 |
2028 | 1,200,000 |
Thereafter | 3,544,000 |
Total | $ 55,227,000 |
Short Term and Long-Term Debt_2
Short Term and Long-Term Debt (Details Narrative) | 1 Months Ended | 12 Months Ended | |||||||||||
Mar. 30, 2023 USD ($) | May 17, 2022 USD ($) shares | May 17, 2022 USD ($) shares | Mar. 17, 2022 USD ($) | Nov. 02, 2021 USD ($) | Oct. 13, 2021 USD ($) | Aug. 01, 2021 USD ($) ft² | Nov. 30, 2021 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Jul. 29, 2022 | May 20, 2021 USD ($) | Mar. 02, 2020 USD ($) $ / shares | |
Short-Term Debt [Line Items] | |||||||||||||
Long term debt current | $ 47,776,000 | $ 47,161,000 | |||||||||||
Long term debt | 55,227,000 | ||||||||||||
Payments to acquire assets | 818,000 | 2,294,000 | |||||||||||
Payments to intangible assets | 508,000 | ||||||||||||
Net book value of assets | 6,417,000 | 13,391,000 | |||||||||||
Interest expense | 553,000 | 126,000 | |||||||||||
BMIC Loan [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 3,000,000 | 547,000 | 3,000,000 | ||||||||||
Maturity date | Oct. 12, 2022 | ||||||||||||
Wilson Loan [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 3,000,000 | 2,131,000 | 3,008,000 | ||||||||||
Maturity date | Oct. 12, 2022 | ||||||||||||
Security Agreement [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 790,000 | 719,000 | |||||||||||
Long term debt current | 112,000 | ||||||||||||
Long term debt | 607,000 | ||||||||||||
Interest expense debt | $ 14,000 | ||||||||||||
Premier Packaging Bank Of America NA [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | 2,932,000 | $ 3,406,000 | |||||||||||
Principal interest percentage | 4.63% | ||||||||||||
Debt financing amount | $ 3,710,000 | ||||||||||||
Long term debt current | 491,000 | ||||||||||||
Long term debt | 2,442,000 | ||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 6,155,000 | ||||||||||||
Principal interest percentage | 4.25% | ||||||||||||
Long term debt current | $ 5,105,000 | 206,000 | |||||||||||
Long term debt | 4,402,000 | ||||||||||||
Debt instrument description | The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5-year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25% for the term of 120 months | ||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | $ 2,829,000 | ||||||||||||
Debt effective interest rate percentage | 4.25% | ||||||||||||
Area of land | ft² | 40,000 | ||||||||||||
Payments to intangible assets | $ 585,000 | ||||||||||||
Net book value of assets | 6,729,000 | ||||||||||||
Debt issuance costs | 50,000 | ||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Facility [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | 4,640,000 | ||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Land [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | 1,600,000 | ||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Tenant Improvements [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | $ 325,000 | ||||||||||||
AMRE Shelton LLC [Member] | Loan Agreement [Member] | Other Intangible Assets [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Estimated useful life | 3 years | ||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 40,300,000 | 41,331,000 | $ 40,193,000 | ||||||||||
Debt instrument description | The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five (25) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full | ||||||||||||
Debt effective interest rate percentage | 8.46% | 4.28% | |||||||||||
Payments to intangible assets | $ 15,901,000 | ||||||||||||
Net book value of assets | $ 52,407,000 | ||||||||||||
Debt issuance costs | 270,000 | ||||||||||||
Maturity date | Nov. 02, 2023 | ||||||||||||
Purchase price | $ 62,000,000 | ||||||||||||
Interest expense | 3,773,000 | 2,418,000 | |||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Extended Maturity [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Maturity date | Nov. 02, 2024 | ||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Minimum [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Estimated useful life | 1 year | ||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Maximum [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Estimated useful life | 11 years | ||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Facility [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | $ 32,100,000 | ||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Land [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | 12,100,000 | ||||||||||||
Pinnacle Bank [Member] | LifeCare Agreement [Member] | Site Improvements [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | $ 1,500,000 | ||||||||||||
Union Bank And Trust Company [Member] | Security Agreement [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Principal interest percentage | 7.44% | ||||||||||||
Unsecured Promissory Note [Member] | American Medical REIT Inc. [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 200,000 | ||||||||||||
Principal interest percentage | 8% | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 5 | ||||||||||||
Warrants and Rights Outstanding | $ 200,000 | ||||||||||||
Alset Note [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | $ 8,350,000 | 8,350,000 | |||||||||
Principal interest percentage | 8% | ||||||||||||
Long term debt | $ 8,805,000 | 8,805,000 | |||||||||||
Interest expense | 677,000 | 346,000 | |||||||||||
Debt instrument maturity date, description | matures in December 2023 | ||||||||||||
Shares issued for convertible debt | shares | 21,366,177 | 21,366,177 | |||||||||||
Accrued unpaid interest | $ 119,000 | $ 119,000 | 119,000 | ||||||||||
Pinnacle Loan [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Debt instrument, face amount | $ 2,990,000 | 17,000 | 60,000 | ||||||||||
Principal interest percentage | 4.28% | ||||||||||||
Payments to intangible assets | $ 29,000 | ||||||||||||
Estimated useful life | 5 years | ||||||||||||
Net book value of assets | 4,450,000 | ||||||||||||
Debt issuance costs | 2,977,000 | 2,952,000 | |||||||||||
Maturity date | Mar. 07, 2024 | ||||||||||||
Purchase price | $ 4,500,000 | ||||||||||||
Interest expense | $ 25,000 | $ 153,000 | |||||||||||
Debt instrument term | 25 years | ||||||||||||
Pinnacle Loan [Member] | Facility [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | $ 3,200,000 | ||||||||||||
Pinnacle Loan [Member] | Land [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | 1,000,000 | ||||||||||||
Pinnacle Loan [Member] | Site and Tenant Improvements [Member] | |||||||||||||
Short-Term Debt [Line Items] | |||||||||||||
Payments to acquire assets | $ 222,000 |
Schedule of Future Minimum Leas
Schedule of Future Minimum Lease Payments (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Lease Liability | ||
2024 | $ 956,000 | |
2025 | 861,000 | |
2026 | 839,000 | |
2027 | 808,000 | |
2028 | 824,000 | |
After | 4,913,000 | |
Total lease payments | 9,201,000 | |
Less: Imputed Interest | (1,598,000) | |
Present value of remaining lease payments | 7,603,000 | |
Current | 686,000 | $ 796,000 |
Noncurrent | $ 6,917,000 | $ 7,820,000 |
Weighted-average remaining lease term (years) | 14 years 3 months 18 days | |
Weighted-average discount rate | 4.10% |
Lease Liability (Details Narrat
Lease Liability (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Lease expense | $ 790,000 | $ 975,000 | |
Minimum [Member] | |||
Remaining lease term | 1 year | ||
Operating lease escalating payment | $ 61,000 | ||
Maximum [Member] | |||
Remaining lease term | 12 years | ||
Operating lease escalating payment | $ 78,000 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) - USD ($) | 12 Months Ended | ||||||||||||||||
Jan. 04, 2024 | Oct. 31, 2023 | Apr. 10, 2023 | May 25, 2022 | May 17, 2022 | May 17, 2022 | May 05, 2022 | Mar. 10, 2022 | Mar. 09, 2022 | Feb. 28, 2022 | Feb. 28, 2022 | Dec. 09, 2019 | Dec. 31, 2023 | Dec. 31, 2022 | Jul. 02, 2022 | Feb. 18, 2022 | Jun. 20, 2013 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Number of shares of common stock, values | $ 268,000 | $ 17,405,000 | |||||||||||||||
Stock issued during period shares acquisitions | 17,570,948 | ||||||||||||||||
Stockholders' equity, reverse stock split | 1 for 20 | ||||||||||||||||
Equity reserve stock split | 140,264,240 | 139,017,000 | |||||||||||||||
Common stock, shares issued | 7,066,772 | 6,950,858 | |||||||||||||||
Common stock, shares outstanding | 7,066,772 | 6,950,858 | |||||||||||||||
Share based compensation expense | $ 0 | $ 4,000 | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares | 5,333 | ||||||||||||||||
Common Stock [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Number of shares of common stock | 62,354 | 2,146,200 | |||||||||||||||
Number of shares of common stock, values | $ 1 | $ 43,000 | |||||||||||||||
True Partners Capital Holdings Limited [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Stock issued during period shares acquisitions | 62,122,908 | 62,122,908 | |||||||||||||||
Share price | $ 0.34 | $ 0.34 | |||||||||||||||
Minimum [Member] | Common Stock [Member] | DSS Bio Health Securities Inc [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Ownership percentage | 12% | ||||||||||||||||
Maximum [Member] | Common Stock [Member] | DSS Bio Health Securities Inc [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Ownership percentage | 88% | ||||||||||||||||
Alset EHome International Inc [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Shares issued for convertible debt | 21,366,177 | 21,366,177 | |||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | |||||||||||||||
Accrued unpaid interest | $ 367,000 | ||||||||||||||||
American Medical REIT Inc. [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Accrued unpaid interest | $ 367,000 | ||||||||||||||||
Alset EHome [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Share price | $ 0.34 | $ 0.41 | |||||||||||||||
Impact BioMedical, Inc. [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Stockholders' equity, reverse stock split | reverse stock split of 1 for 55 | ||||||||||||||||
Equity reserve stock split | 70,496,041 | ||||||||||||||||
Common stock, shares issued | 3,877,282,251 | 3,877,282,251 | |||||||||||||||
Common stock, shares outstanding | 3,877,282,251 | 3,877,282,251 | |||||||||||||||
Impact BioMedical, Inc. [Member] | Series A Convertible Preferred Stock [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Equity reserve stock split | 60,496,041 | ||||||||||||||||
Impact BioMedical, Inc. [Member] | Common Stock [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Equity reserve stock split | 60,496,041 | ||||||||||||||||
Stock Purchase Agreement [Member] | Alset EHome International Inc [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Number of shares of common stock | 3,986,877 | 44,619,423 | 44,619,423 | ||||||||||||||
Issued price per share | $ 0.3810 | $ 0.3810 | |||||||||||||||
Number of shares of common stock, values | $ 1,519,000 | $ 17,000,000 | $ 17,000,000 | ||||||||||||||
Payments for proceeds from previous acquisition | $ 1,519,000 | ||||||||||||||||
Stock Purchase Agreement [Member] | Alset EHome International Inc [Member] | Minimum [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Number of shares of common stock | 3,986,877 | ||||||||||||||||
Employment Agreement [Member] | Heng Fai Ambrose Chan [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Number of shares of common stock | 15,389,995 | 894,084 | |||||||||||||||
Number of shares of common stock, values | $ 5,848,000 | $ 340,000 | |||||||||||||||
Employment Agreement [Member] | Frank Heuszel [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Number of shares of common stock | 62,354 | 63,205 | |||||||||||||||
Number of shares of common stock, values | $ 268,000 | $ 29,000 | |||||||||||||||
2020 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Authorized shares | 241,204 | 460,846 | |||||||||||||||
Debt Instrument, Redemption, Description | In addition, on the first day of each calendar year, for a period of not more than ten (10) years, commencing January 1, 2021, or the first business day of the calendar year if the first day of the calendar year falls on a Saturday or Sunday, the shares available under this plan will automatically increase in an amount equal to the lesser of (i) five percent (5%) of the total number of shares of Common Stock outstanding as of December 31 of the preceding fiscal year or (ii) such number of shares of Common Stock as determined by the Board of Directors. | ||||||||||||||||
2013 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | |||||||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
Authorized shares | 0 | 50,000 |
Schedule of Income Tax Provisio
Schedule of Income Tax Provision (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Currently payable: | ||
Federal | $ 15,000 | |
State | 4,000 | |
Foreign | 119,000 | |
Total currently payable | 4,000 | 134,000 |
Deferred: | ||
Federal | (5,392,000) | (14,839,000) |
State | (79,000) | (492,000) |
Foreign | (48,000) | (58,000) |
Total deferred | (5,519,000) | (15,390,000) |
Less: increase in allowance | 5,519,000 | 15,427,000 |
Net deferred | 38,000 | |
Total income tax loss (benefit) | $ 4,000 | $ 172,000 |
Schedule of Deferred Tax Assets
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
Deferred tax assets: | ||
Net operating loss carry forwards | $ 21,496,000 | $ 24,975,000 |
Net operating loss IRC 382 limited | 9,634,000 | 9,634,000 |
Unrealized loss on securities | 4,655,000 | 5,753,000 |
Equity issued for services | 190,000 | 190,000 |
Goodwill and other intangibles | 63,000 | 34,000 |
Investment in pass-through entity | 11,000 | 11,000 |
Deferred revenue | 176,000 | 176,000 |
Operating Lease Liability | 1,713,000 | 1,935,000 |
Depreciation and amortization | 1,000 | 24,000 |
Other | 2,507,000 | 696,000 |
Gross deferred tax assets | 40,446,000 | 33,794,000 |
Deferred tax liabilities: | ||
Goodwill and other intangibles | 3,369,000 | 2,822,000 |
Depreciation and amortization | 614,000 | (194,000) |
Right -of-use asset | 1,625,000 | 1,846,000 |
Gross deferred tax liabilities | 5,608,000 | 4,474,000 |
Less: valuation allowance | (34,838,000) | (29,357,000) |
Net deferred tax liabilities | $ (38,000) |
Schedule of Effective Income Ta
Schedule of Effective Income Tax Rate Reconciliation (Details) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||
Statutory United States federal rate | 21% | 21% |
State income taxes net of federal benefit | 0.38% | 0.51% |
Permanent differences | (6.68%) | 0.03% |
Other | (9.04%) | 0.93% |
Foreign taxes | (0.07%) | |
Change in valuation allowance | (5.66%) | (22.66%) |
Effective rate | (0.25%) |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2020 | |
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | $ 43,800,000 | ||
Deferred tax assets valuation allowance | $ 5,500,000 | $ 15,400,000 | $ 2,900,000 |
Net operating loss carryforwards expiration date description | expire through 2043 | ||
Changes in deferred tax liabilities valuation allowance | $ 1,100,000 | 9,900,000 | |
Income Tax Examination, Penalties and Interest Expense | 0 | 0 | |
CALIFORNIA | |||
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | 20,700,000 | 43,600,000 | |
Federal [Member] | |||
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | $ 138,900,000 | $ 108,400,000 |
Defined Contribution Pension _2
Defined Contribution Pension Plan (Details Narrative) - USD ($) | 12 Months Ended | ||
Jan. 02, 2018 | Dec. 31, 2023 | Dec. 31, 2022 | |
Multiemployer Plan [Line Items] | |||
Employee's contribution maximum percentage | 100% | ||
Contributions by company | $ 124,000 | $ 124,000 | |
Additional Contribution [Member] | |||
Multiemployer Plan [Line Items] | |||
Employee's contribution maximum percentage | 50% | ||
Employer match percentage | 3.50% |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) | Dec. 20, 2022 | Mar. 19, 2022 | Feb. 15, 2021 |
Maiden Biosciences Inc [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Loss contingency allegations | This lawsuit relates to two promissory notes executed by RBC in the 4th quarter of 2019 in favor of Decentralized and HWH, totaling approximately $1,000,000. Maiden, a 2020 default judgment creditor of RBC, in the principal amount of $4,329,000, now complains about those notes, the funding of those notes, the subsequent default of those notes by RBC, and HWH and Decentralized’s subsequent Article 9 foreclosure or deed-in-lieu debt conveyances. In the instant lawsuit, Maiden first asserted claims against Defendants for unjust enrichment, fraudulent transfer under the Texas Uniform Fraudulent Transfer Act (“TUFTA”), and violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”). Maiden also sought a judgment from the court declaring: “(1) Defendants lacked a valid security interest in RBC and RBC Subsidiaries’ assets and therefore lacked the authority to sell the assets during the public foreclosure sale; (2) Defendant Heuszel’s low bid at the public foreclosure sale was invalid and void; (3) the public foreclosure sale was conducted in a commercially unreasonable manner; and (4) Defendants do not have the legal authority to transfer RBC and RBC’s Subsidiaries assets to Heuszel and HWH.” Maiden sought to recover from Defendants: (1) treble damages or, alternatively, damages in the amount of their underlying judgment plus the other creditors’ claims or the value of the assets transferred, whichever is less, plus punitive or exemplary damages; (2) pre- and post-judgment interest; and (3) attorneys’ fees and cost | ||
License Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Sale of royalty percentage | 5.50% | ||
Development cost, percent | 50% | ||
Development costs | $ 1,250,000 | ||
License Agreement [Member] | Bio Medical [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Loss contingency allegations | (1) the evidence does not support Maiden’s claim against the Company; (2) recovery of exemplary damages under TUFTA is unsupported; and (3) the evidence established that the DSS Defendants are entitled to judgment in their favor on their affirmative defenses. After the DSS Defendants filed their post-judgment motions, the case was settled for $8.75 million, the Court’s December 20, 2022 judgment was vacated, and the case was dismissed with prejudice | In exchange, the Licensee shall pay the Company a royalty of 5.5% of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50% of the development costs provided that the development costs shall not exceed $1,250,000. As of December 31, 2023 and December 31, 2022, $200,000 and $0, respectively, has been accrued for in relation to the Equivir License as development of the Equivir technology. |
Schedule of Supplemental Cash F
Schedule of Supplemental Cash Flow Information (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Supplemental Cash Flow Elements [Abstract] | ||
Cash paid for interest | $ 4,812,000 | $ 3,270,000 |
Right of use asset | 9,568,000 | |
Shares issued in lieu of bonus cash | 268,000 | 6,221,000 |
Purchase of notes receivable with company stock | 8,717,000 | |
Purchase of marketable security with Company stock | 7,169,000 | |
Third party Note receivable received in lieu of cash | $ 1,100,000 |
Schedule of Operations by Repor
Schedule of Operations by Reportable Segment (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Segment Reporting Information [Line Items] | ||
Revenue | $ 30,258,000 | $ 47,307,000 |
Interest expense | 553,000 | 126,000 |
Interest Income | 1,289,000 | 629,000 |
Operating Segments [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 30,258,000 | 47,307,000 |
Assets held for sale | 51,595,000 | |
Depreciation and amortization | 5,206,000 | 11,463,000 |
Cost of revenue | 26,647,000 | 40,247,000 |
Interest expense | 4,812,000 | 126,000 |
Interest Income | 1,289,000 | |
Stock based compensation | 4,000 | |
Net income (loss) from continuing operations | (97,503,000) | (69,662,000) |
Capital expenditures | 818,000 | 2,294,000 |
Identifiable assets | 153,192,000 | 248,915,000 |
Operating Segments [Member] | Product Packaging [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 18,497,000 | 17,973,000 |
Assets held for sale | ||
Depreciation and amortization | 761,000 | 715,000 |
Cost of revenue | 15,282,000 | 16,960,000 |
Interest expense | 185,000 | 140,000 |
Interest Income | ||
Stock based compensation | 1,000 | |
Net income (loss) from continuing operations | 327,000 | (1,234,000) |
Capital expenditures | 689,000 | 1,612,000 |
Identifiable assets | 21,508,000 | 24,641,000 |
Operating Segments [Member] | Commercial Banking [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 385,000 | 764,000 |
Assets held for sale | ||
Depreciation and amortization | ||
Cost of revenue | 1,139,000 | 1,041,000 |
Interest expense | ||
Interest Income | ||
Stock based compensation | ||
Net income (loss) from continuing operations | (31,497,000) | (459,000) |
Capital expenditures | ||
Identifiable assets | 12,285,000 | 48,240,000 |
Operating Segments [Member] | Direct Marketing Online Sales [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 6,088,000 | 21,989,000 |
Assets held for sale | ||
Depreciation and amortization | 157,000 | 413,000 |
Cost of revenue | 2,075,000 | 9,828,000 |
Interest expense | (5,000) | 1,000 |
Interest Income | 986,000 | |
Stock based compensation | ||
Net income (loss) from continuing operations | (32,860,000) | (40,182,000) |
Capital expenditures | 4,000 | 384,000 |
Identifiable assets | 6,303,000 | 27,526,000 |
Operating Segments [Member] | Biotechnology [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | ||
Assets held for sale | ||
Depreciation and amortization | 1,163,000 | 1,113,000 |
Cost of revenue | 77,000 | |
Interest expense | ||
Interest Income | 155,000 | |
Stock based compensation | ||
Net income (loss) from continuing operations | (7,168,000) | (7,462,000) |
Capital expenditures | 17,000 | 276,000 |
Identifiable assets | 49,305,000 | 53,069,000 |
Operating Segments [Member] | Securities [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 5,288,000 | 6,581,000 |
Assets held for sale | 51,595,000 | |
Depreciation and amortization | 3,047,000 | 9,093,000 |
Cost of revenue | 8,003,000 | 11,784,000 |
Interest expense | 4,632,000 | (15,000) |
Interest Income | 148,000 | |
Stock based compensation | ||
Net income (loss) from continuing operations | (19,792,000) | (8,238,000) |
Capital expenditures | 104,000 | 18,000 |
Identifiable assets | 59,345,000 | 83,873,000 |
Operating Segments [Member] | Corporate Segment [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | ||
Assets held for sale | ||
Depreciation and amortization | 78,000 | 129,000 |
Cost of revenue | 71,000 | 634,000 |
Interest expense | ||
Interest Income | ||
Stock based compensation | 3,000 | |
Net income (loss) from continuing operations | (6,513,000) | (12,084,000) |
Capital expenditures | 4,000 | 4,000 |
Identifiable assets | $ 4,446,000 | $ 11,566,000 |
Schedule of Disaggregation of R
Schedule of Disaggregation of Revenue (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Segment Reporting Information [Line Items] | ||
Revenue | $ 30,258,000 | $ 47,307,000 |
Printed Products [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 18,497,000 | 17,973,000 |
Direct Marketing [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 6,088,000 | 21,989,000 |
Rental Revenue Income [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 3,647,000 | 6,287,000 |
Commission Revenue [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 1,641,000 | 294,000 |
Management Revenue Fee Income [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 134,000 | |
Net Investment Revenue Income [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 385,000 | 630,000 |
Packaging Printing and Fabrication [Member] | Printed Products [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 18,036,000 | 17,499,000 |
Commercial and Security Printing [Member] | Printed Products [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 461,000 | 474,000 |
Direct Marketing Internet Sales [Member] | Direct Marketing [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 6,088,000 | 21,989,000 |
Rental Income [Member] | Rental Revenue Income [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 3,647,000 | 6,287,000 |
Commission Income [Member] | Commission Revenue [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 1,641,000 | 294,000 |
Management Fee Income [Member] | Management Revenue Fee Income [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | 134,000 | |
Net Investment Income [Member] | Net Investment Revenue Income [Member] | ||
Segment Reporting Information [Line Items] | ||
Revenue | $ 385,000 | $ 630,000 |
Segment Information (Details Na
Segment Information (Details Narrative) | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Non-US [Member] | ||
Revenue, Major Customer [Line Items] | ||
Concentration risk percentage | 7% | 11% |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 1 Months Ended | 12 Months Ended | ||||||||||||||||
Aug. 29, 2022 | Aug. 09, 2022 | Jul. 26, 2022 | May 17, 2022 | May 17, 2022 | Mar. 09, 2022 | Feb. 28, 2022 | Feb. 28, 2022 | Oct. 13, 2021 | Mar. 18, 2021 | Mar. 18, 2021 | Oct. 31, 2017 | Nov. 30, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Jul. 02, 2022 | Feb. 18, 2022 | Mar. 02, 2020 | |
Marketable securities | $ 10,000,000 | |||||||||||||||||
Unrealized gain on investment | (17,325,000) | $ (17,976,000) | ||||||||||||||||
Principal amount | 55,227,000 | |||||||||||||||||
Interest expense | 553,000 | 126,000 | ||||||||||||||||
Number of shares of common stock, value | $ 268,000 | $ 17,405,000 | ||||||||||||||||
Conversion of stock | 140,264,240 | 139,017,000 | ||||||||||||||||
Stock issued for acquisition | 17,570,948 | |||||||||||||||||
Long term portion of notes receivable | $ 8,772,000 | $ 11,719,000 | ||||||||||||||||
Note 11 [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 100,000 | $ 1,000,000 | ||||||||||||||||
Debt instrument interest rate | 8% | 8% | ||||||||||||||||
Maturity date | Aug. 29, 2025 | Jul. 26, 2024 | ||||||||||||||||
Notes and loans receivable gross current | 939,000 | 924,000 | ||||||||||||||||
Unamortized origination fees | 20,000 | 66,000 | ||||||||||||||||
Long term portion of notes receivable | 24,000 | 76,000 | ||||||||||||||||
Note 10 [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 100,000 | |||||||||||||||||
Debt instrument interest rate | 8% | |||||||||||||||||
Maturity date | Aug. 29, 2025 | |||||||||||||||||
Notes and loans receivable gross current | 100,000 | 100,000 | ||||||||||||||||
Long term portion of notes receivable | 24,000 | 76,000 | ||||||||||||||||
BMIC Loan [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | 547,000 | 3,000,000 | |||||||||||||||
Maturity date | Oct. 12, 2022 | |||||||||||||||||
Wilson Loan [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 3,000,000 | 2,131,000 | 3,008,000 | |||||||||||||||
Maturity date | Oct. 12, 2022 | |||||||||||||||||
Impact Oncology PTE Ltd. [Member] | ||||||||||||||||||
Investment owned balance shares | 2,480,000 | 2,480,000 | ||||||||||||||||
Consideration transferred | $ 2,480,000 | $ 2,480,000 | ||||||||||||||||
Options to purchase additional shares | 250,000 | |||||||||||||||||
Alset Note [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | $ 8,350,000 | 8,350,000 | ||||||||||||||
Debt instrument interest rate | 8% | |||||||||||||||||
Debt instrument maturity date, description | matures in December 2023 | |||||||||||||||||
Principal amount | $ 8,805,000 | 8,805,000 | ||||||||||||||||
Shares issued for convertible debt | 21,366,177 | 21,366,177 | ||||||||||||||||
Accrued unpaid interest | $ 119,000 | $ 119,000 | 119,000 | |||||||||||||||
Interest expense | $ 677,000 | 346,000 | ||||||||||||||||
Alset International Limited [Member] | ||||||||||||||||||
Investment owned balance shares | 127,179,291 | |||||||||||||||||
Warrants percentage | 4% | |||||||||||||||||
Marketable securities | $ 3,269,000 | 3,319,000 | ||||||||||||||||
Unrealized gain on investment | $ 50,000 | $ 1,590,000 | ||||||||||||||||
American Medical REIT Inc. [Member] | Unsecured Promissory Note [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 200,000 | |||||||||||||||||
Debt instrument interest rate | 8% | |||||||||||||||||
Exercise price of warrants | $ 5 | |||||||||||||||||
Warrants and rights outstanding | $ 200,000 | |||||||||||||||||
Impact Oncology PTE Ltd. [Member] | ||||||||||||||||||
Investment owned balance shares | 2,480,000 | 2,480,000 | ||||||||||||||||
Alset EHome International Inc [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 8,350,000 | $ 8,350,000 | ||||||||||||||||
Shares issued for convertible debt | 21,366,177 | 21,366,177 | ||||||||||||||||
Alset EHome International Inc [Member] | Stock Purchase Agreement [Member] | ||||||||||||||||||
Issuance of common stock, net of expenses, shares | 3,986,877 | 44,619,423 | 44,619,423 | |||||||||||||||
Issued price per share | $ 0.3810 | $ 0.3810 | ||||||||||||||||
Number of shares of common stock, value | $ 1,519,000 | $ 17,000,000 | $ 17,000,000 | |||||||||||||||
Payments for proceeds from previous acquisition | $ 1,519,000 | |||||||||||||||||
Alset EHome International Inc [Member] | Stock Purchase Agreement [Member] | Minimum [Member] | ||||||||||||||||||
Issuance of common stock, net of expenses, shares | 3,986,877 | |||||||||||||||||
HWH International Inc [Member] | ||||||||||||||||||
Debt instrument, face amount | $ 50,000 | |||||||||||||||||
Issued price per share | $ 0.15 | |||||||||||||||||
Conversion of stock | 333,333 | |||||||||||||||||
Warrants to purchase | 333,333 | |||||||||||||||||
Cancelleation of warrants and notes | $ 78,635.62 | |||||||||||||||||
True Partners Capital Holdings Limited [Member] | ||||||||||||||||||
Stock issued for acquisition | 62,122,908 | |||||||||||||||||
Number of shares exchanged | 17,570,948 | |||||||||||||||||
Alset EHome [Member] | ||||||||||||||||||
Share price | $ 0.34 | $ 0.41 |